Enrichment analysis report,,,,,,,,,,,,,
Enrichment by Pathway Maps,,,,,up_genes_int_061520_genelist,,,,up_genes_rna_061620_genelist,,,,
#,Maps,Total,min(pValue),Min FDR,p-value,FDR,In Data,"Network Objects from
Active Data",p-value,FDR,In Data,"Network Objects from
Active Data",
1,Breast cancer (general schema),41,2.198E-08,2.101E-05,2.198E-08,2.101E-05,10,"PTHR1, ESR1 (nuclear), Androgen receptor, ESR1 (membrane), TGF-beta, PR (membrane), GHR, Prolactin receptor, PR (nuclear), ErbB3",2.216E-07,1.890E-04,9,"PTHR1, ESR1 (nuclear), Androgen receptor, ESR1 (membrane), TGF-beta, PR (membrane), GHR, Prolactin receptor, PR (nuclear)",
2,Regulation of IGF family activity in colorectal cancer,30,4.373E-05,1.297E-02,5.365E-05,1.932E-02,6,"IBP4, IBP5, CEACAM5, IBP2, Cystatin SN, IBP",4.373E-05,1.297E-02,6,"IBP4, IBP5, CEACAM5, IBP2, Cystatin SN, IBP",
3,G protein-coupled receptors signaling in lung cancer,76,4.562E-05,1.297E-02,6.061E-05,1.932E-02,9,"VIP receptor 1, IL8RA, PGE2R3, Galpha(i)-specific peptide GPCRs, GRP-R, BDKRB2, CCR5, VIP receptor 2, Galpha(q)-specific peptide GPCRs",4.562E-05,1.297E-02,9,"VIP receptor 1, IL8RA, PGE2R3, Galpha(i)-specific peptide GPCRs, GRP-R, BDKRB2, CCR5, VIP receptor 2, Galpha(q)-specific peptide GPCRs",
4,Action of lithium on synaptic transmission and autophagy,35,9.920E-04,1.755E-01,1.168E-03,1.755E-01,5,"P2X2, PP2A regulatory, Adenylate cyclase, Adenylate cyclase type V, Adenylate cyclase type II",9.920E-04,1.824E-01,5,"P2X2, PP2A regulatory, Adenylate cyclase, Adenylate cyclase type V, Adenylate cyclase type II",
5,Dysregulation of direct glucose-induced inhibition of Glucagon secretion from alpha-cells in type 2 diabetes  ,53,1.102E-03,1.755E-01,1.330E-03,1.755E-01,6,"Kir6.2, PC2, MaxiK alpha subunit, CACNA1H, SUR1, CACNA1D",1.102E-03,1.824E-01,6,"Kir6.2, PC2, MaxiK alpha subunit, CACNA1H, SUR1, CACNA1D",
6,Pro-oncogenic action of Androgen receptor in breast cancer,35,1.168E-03,1.755E-01,1.168E-03,1.755E-01,5,"Androgen receptor, FASN, HNF3-alpha, PIP, ErbB3",4.236E-02,6.339E-01,3,"Androgen receptor, HNF3-alpha, PIP",
7,Regulation of Adenylate cyclase and IMPA1 by lithium in major depressive disorder,22,1.283E-03,1.755E-01,1.469E-03,1.755E-01,4,"P2X2, Adenylate cyclase, Adenylate cyclase type II, Alpha-2A adrenergic receptor",1.283E-03,1.824E-01,4,"P2X2, Adenylate cyclase, Adenylate cyclase type II, Alpha-2A adrenergic receptor",
8,PR action in breast cancer: stimulation of cell growth and proliferation,36,1.332E-03,1.755E-01,1.332E-03,1.755E-01,5,"ESR1 (nuclear), ESR1 (membrane), PR (membrane), PR (nuclear), ErbB3",8.097E-03,3.453E-01,4,"ESR1 (nuclear), ESR1 (membrane), PR (membrane), PR (nuclear)",
9,Putative pathways of hormone action in neurofibromatosis type 1,25,2.105E-03,2.304E-01,2.406E-03,2.304E-01,4,"ESR1 (nuclear), ESR1 (membrane), GHR, PR (nuclear)",2.105E-03,2.565E-01,4,"ESR1 (nuclear), ESR1 (membrane), GHR, PR (nuclear)",
10,Regulation of metabolism_Bile acids regulation of glucose and lipid metabolism via FXR,41,2.410E-03,2.304E-01,2.410E-03,2.304E-01,5,"FASN, ACACB, HNF3-alpha, HNF3, F16P",1.277E-02,4.241E-01,4,"ACACB, HNF3-alpha, HNF3, F16P",
11,Signal transduction_Modulation of calcium and potassium channels by Adenosine A1 receptor,43,2.545E-03,2.591E-01,2.982E-03,2.591E-01,5,"Kir6.2, MaxiK alpha subunit, SK2, Adenylate cyclase, SUR1",2.545E-03,2.714E-01,5,"Kir6.2, MaxiK alpha subunit, SK2, Adenylate cyclase, SUR1",
12,Regulation of relaxation of airway smooth muscle cells,45,3.116E-03,2.741E-01,3.646E-03,2.741E-01,5,"VIP receptor 1, PGE2R3, VIP receptor 2, Adenylate cyclase type IV, Adenylate cyclase type II",3.116E-03,2.927E-01,5,"VIP receptor 1, PGE2R3, VIP receptor 2, Adenylate cyclase type IV, Adenylate cyclase type II",
13,TMPRSS2-ERG fusion in Prostate Cancer,46,3.434E-03,2.741E-01,4.014E-03,2.741E-01,5,"Androgen receptor, PEP-19, ERG, DSCAM, IGSF5 (JAM4)",3.434E-03,2.927E-01,5,"Androgen receptor, PEP-19, ERG, DSCAM, IGSF5 (JAM4)",
14,Neurophysiological process_Dopamine D2 receptor signaling in CNS,47,3.774E-03,2.810E-01,4.409E-03,2.810E-01,5,"TY3H, Kir3.1, Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",3.774E-03,2.927E-01,5,"TY3H, Kir3.1, Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",
15,EGFR signaling in Prostate Cancer,46,4.014E-03,2.741E-01,4.014E-03,2.741E-01,5,"Androgen receptor, Tuberin, p27KIP1, N-Ras, ErbB3",6.459E-01,8.219E-01,1,Androgen receptor,
16,Retinoic acid maintains mucocilliary differentiation and mucins expression in normal and asthmatic airway epithelium,30,4.180E-03,2.845E-01,4.761E-03,2.845E-01,4,"Mucin 5B, Mucin 2, Mucin 5AC, Mucin 6",4.180E-03,2.971E-01,4,"Mucin 5B, Mucin 2, Mucin 5AC, Mucin 6",
17,Immune response_IL-4-responsive genes in type 2 immunity,70,4.597E-03,2.989E-01,5.485E-03,2.989E-01,6,"IL-19, GATA-3, TFF3, Mucin 5AC, IGHG4, IGHE",4.597E-03,3.017E-01,6,"IL-19, GATA-3, TFF3, Mucin 5AC, IGHG4, IGHE",
18,Proteases and EGFR-activated mucin production in airway epithelium in COPD,50,5.759E-03,2.989E-01,5.759E-03,2.989E-01,5,"PTEN, Mucin 5B, Mucin 5AC, Bcl-2, ErbB3",9.992E-02,7.672E-01,3,"Mucin 5B, Mucin 5AC, Bcl-2",
19,Development_Self-renewal and pluripotency maintenance of human embryonic stem cells,33,5.925E-03,2.989E-01,6.735E-03,2.989E-01,4,"SOX2, PBX1, CG alpha, LIN-28",5.925E-03,3.218E-01,4,"SOX2, PBX1, CG alpha, LIN-28",
20,LRRK2 in neurons in Parkinson's disease,33,5.925E-03,2.989E-01,6.735E-03,2.989E-01,4,"eEF1A2, Tau (MAPT), eEF1A, LRRK2",5.925E-03,3.218E-01,4,"eEF1A2, Tau (MAPT), eEF1A, LRRK2",
21,Putative pathways for stimulation of fat cell differentiation by Bisphenol A,32,6.026E-03,2.989E-01,6.026E-03,2.989E-01,4,"ESR1 (nuclear), Androgen receptor, FASN, C/EBPalpha",3.369E-02,6.115E-01,3,"ESR1 (nuclear), Androgen receptor, C/EBPalpha",
22,Neurophysiological process_Regulation of intrinsic membrane properties and excitability of cortical pyramidal neurons,74,6.035E-03,2.989E-01,7.181E-03,2.989E-01,6,"MaxiK alpha subunit, SK2, Kir2.2, Adenylate cyclase, CACNA1D, Alpha-2A adrenergic receptor",6.035E-03,3.218E-01,6,"MaxiK alpha subunit, SK2, Kir2.2, Adenylate cyclase, CACNA1D, Alpha-2A adrenergic receptor",
23,Development_Schema: Methods of somatic cell reprogramming into induced pluripotent stem cells,6,6.988E-03,2.989E-01,7.504E-03,2.989E-01,2,"SOX2, LIN-28",6.988E-03,3.288E-01,2,"SOX2, LIN-28",
24,Neurophysiological process_Thyroliberin in cell hyperpolarization and excitability,35,7.323E-03,3.057E-01,8.313E-03,3.057E-01,4,"Kir3.1, MaxiK alpha subunit, Thyroliberin, KCNH7",7.323E-03,3.288E-01,4,"Kir3.1, MaxiK alpha subunit, Thyroliberin, KCNH7",
25,Development_Extraembryonic differentiation of embryonic stem cells,35,7.323E-03,3.057E-01,8.313E-03,3.057E-01,4,"SOX2, GATA-3, MSX-2, HNF3-alpha",7.323E-03,3.288E-01,4,"SOX2, GATA-3, MSX-2, HNF3-alpha",
26,"Development_Insulin, IGF-1 and TNF-alpha in brown adipocyte differentiation",53,7.376E-03,2.989E-01,7.376E-03,2.989E-01,5,"Adiponectin, FASN, p27KIP1, Perilipin, C/EBPalpha",1.139E-01,7.672E-01,3,"Adiponectin, Perilipin, C/EBPalpha",
27,Higher ESR1 / ESR2 ratio in breast cancer,36,9.186E-03,3.253E-01,9.186E-03,3.253E-01,4,"ESR1 (nuclear), PTEN, p27KIP1, ErbB3",5.561E-01,8.219E-01,1,ESR1 (nuclear),
28,Tinnitus-associated changes in auditory pathway ,82,9.852E-03,3.320E-01,1.166E-02,3.320E-01,6,"GABA-A receptor gamma-2 subunit, mGluR4A, GRIK4, NR1, GABA-A receptor delta subunit, GABA-A receptor gamma-3 subunit",9.852E-03,4.002E-01,6,"GABA-A receptor gamma-2 subunit, mGluR4A, GRIK4, NR1, GABA-A receptor delta subunit, GABA-A receptor gamma-3 subunit",
29,Main pathways of Schwann cells transformation in neurofibromatosis type 1 ,80,1.039E-02,3.310E-01,1.039E-02,3.310E-01,6,"PTEN, Tuberin, N-Ras, B-FABP, Bcl-2, ErbB3",5.352E-01,8.219E-01,2,"B-FABP, Bcl-2",
30,CCL2 in Prostate Cancer,20,1.040E-02,3.310E-01,1.040E-02,3.310E-01,3,"PTEN, Tuberin, PI3K reg class IB (p101)",3.629E-01,8.219E-01,1,PI3K reg class IB (p101),
31,Signal transduction_Leptin signaling in non-neuronal cells,58,1.073E-02,3.310E-01,1.073E-02,3.310E-01,5,"Kir6.2, PTEN, ACACB, Bcl-2, SUR1",3.999E-02,6.339E-01,4,"Kir6.2, ACACB, Bcl-2, SUR1",
32,Putative role of Estrogen receptor and Androgen receptor signaling in progression of lung cancer,58,1.073E-02,3.310E-01,1.073E-02,3.310E-01,5,"ESR1 (nuclear), Androgen receptor, ESR1 (membrane), Tuberin, Bcl-2",3.999E-02,6.339E-01,4,"ESR1 (nuclear), Androgen receptor, ESR1 (membrane), Bcl-2",
33,Autocrine Somatotropin signaling in breast cancer,39,1.073E-02,3.320E-01,1.216E-02,3.320E-01,4,"TFF3, CISH, Bcl-2, GHR",1.073E-02,4.006E-01,4,"TFF3, CISH, Bcl-2, GHR",
34,Role of ZNF202 in regulation of expression of genes involved in atherosclerosis,21,1.080E-02,3.320E-01,1.193E-02,3.320E-01,3,"ABCG1, IA-1, HDL proteins",1.080E-02,4.006E-01,3,"ABCG1, IA-1, HDL proteins",
35,Th2-cytokines-induced mucous metaplasia in asthma,40,1.172E-02,3.523E-01,1.327E-02,3.523E-01,4,"PGE2R3, HAG-2, Mucin 5AC, PDEF",1.172E-02,4.167E-01,4,"PGE2R3, HAG-2, Mucin 5AC, PDEF",
36,Cell cycle progression in Prostate Cancer,39,1.216E-02,3.320E-01,1.216E-02,3.320E-01,4,"Androgen receptor, Tuberin, p27KIP1, Prolactin receptor",2.154E-01,8.219E-01,2,"Androgen receptor, Prolactin receptor",
37,Androgen receptor activation and downstream signaling in Prostate cancer,110,1.377E-02,3.557E-01,1.377E-02,3.557E-01,7,"Androgen receptor, PTEN, HNF3-alpha, N-Ras, FOLH1 (GCP2), PSCA, Clusterin",9.906E-02,7.672E-01,5,"Androgen receptor, HNF3-alpha, FOLH1 (GCP2), PSCA, Clusterin",
38,Estradiol metabolism,42,1.387E-02,3.655E-01,1.568E-02,3.655E-01,4,"SULT1A1, UGT2B11, UGT2B28, UGT2B17",1.387E-02,4.241E-01,4,"SULT1A1, UGT2B11, UGT2B28, UGT2B17",
39,PXR-mediated direct regulation of xenobiotic metabolizing enzymes / Human version,42,1.387E-02,3.655E-01,1.568E-02,3.655E-01,4,"S14 protein, CYP2A6, CYP2B6, OATP-A",1.387E-02,4.241E-01,4,"S14 protein, CYP2A6, CYP2B6, OATP-A",
40,Cytoskeleton remodeling_ESR1 action on cytoskeleton remodeling and cell migration,23,1.392E-02,3.655E-01,1.535E-02,3.655E-01,3,"ESR1 (nuclear), ESR1 (membrane), EBP50",1.392E-02,4.241E-01,3,"ESR1 (nuclear), ESR1 (membrane), EBP50",
41,Prostaglandins and leukotrienes-mediated induction of expression of mucins in normal and asthmatic epithelium ,43,1.503E-02,3.775E-01,1.698E-02,3.775E-01,4,"Mucin 5B, Mucin 2, Mucin 5AC, Adenylate cyclase",1.503E-02,4.274E-01,4,"Mucin 5B, Mucin 2, Mucin 5AC, Adenylate cyclase",
42,"POMC, alpha-MSH and AGRP in regulation of food intake and energy expenditure in obesity in hypothalamus",43,1.503E-02,3.775E-01,1.698E-02,3.775E-01,4,"PC2, Adenylate cyclase type IV, Adenylate cyclase type II, Thyroliberin",1.503E-02,4.274E-01,4,"PC2, Adenylate cyclase type IV, Adenylate cyclase type II, Thyroliberin",
43,Inhibition of GTPase prenylation by statins in asthma and COPD,42,1.568E-02,3.655E-01,1.568E-02,3.655E-01,4,"PTEN, RhoB, p27KIP1, Mucin 5AC",2.402E-01,8.219E-01,2,"RhoB, Mucin 5AC",
44,G-protein signaling_Regulation of Cyclic AMP levels by ACM,45,1.754E-02,4.024E-01,1.978E-02,4.024E-01,4,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II, PDE1B",1.754E-02,4.825E-01,4,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II, PDE1B",
45,Development_Ligand-independent activation of ESR1 and ESR2,44,1.835E-02,3.980E-01,1.835E-02,3.980E-01,4,"ESR1 (nuclear), TFF1, Adenylate cyclase type V, ErbB3",7.424E-02,7.539E-01,3,"ESR1 (nuclear), TFF1, Adenylate cyclase type V",
46,Ligand-independent activation of Androgen receptor in Prostate Cancer,67,1.915E-02,3.980E-01,1.915E-02,3.980E-01,5,"Androgen receptor, PP2A regulatory, N-Ras, Prolactin receptor, ErbB3",1.874E-01,8.219E-01,3,"Androgen receptor, PP2A regulatory, Prolactin receptor",
47,"Role of microRNAs in cell migration, survival and angiogenesis in colorectal cancer",67,1.915E-02,3.980E-01,1.915E-02,3.980E-01,5,"PTEN, RhoB, PDCD4, Bcl-2, Clusterin",6.204E-02,7.539E-01,4,"RhoB, PDCD4, Bcl-2, Clusterin",
48,Signal transduction_mTORC2 downstream signaling,68,2.029E-02,4.042E-01,2.029E-02,4.042E-01,5,"FASN, Tuberin, SLC12A1, p27KIP1, PREX1",4.495E-01,8.219E-01,2,"SLC12A1, PREX1",
49,Signal transduction_Adenosine A3 receptor signaling pathway,48,2.175E-02,4.046E-01,2.449E-02,4.046E-01,4,"PI3K reg class IB (p101), Rho GTPase, Adenylate cyclase, Bcl-2",2.175E-02,5.522E-01,4,"PI3K reg class IB (p101), Rho GTPase, Adenylate cyclase, Bcl-2",
50,Mitogenic action of ESR1 (membrane) in breast cancer,47,2.285E-02,4.046E-01,2.285E-02,4.046E-01,4,"ESR1 (nuclear), ESR1 (membrane), p27KIP1, ErbB3",2.817E-01,8.219E-01,2,"ESR1 (nuclear), ESR1 (membrane)",
51,Th1 and Th17 cells in an autoimmune mechanism of emphysema formation in smokers,28,2.374E-02,4.046E-01,2.610E-02,4.046E-01,3,"Alpha 1-antitrypsin, ROR-gamma, CCR5",2.374E-02,5.522E-01,3,"Alpha 1-antitrypsin, ROR-gamma, CCR5",
52,"Mechanism of Pioglitazone/Glimepiride and Rosiglitazone/Glimepiride cooperative action in Diabetes mellitus, Type 2",11,2.381E-02,4.046E-01,2.550E-02,4.046E-01,2,"Kir6.2, SUR1",2.381E-02,5.522E-01,2,"Kir6.2, SUR1",
53,Main genetic and epigenetic alterations in lung cancer,48,2.449E-02,4.046E-01,2.449E-02,4.046E-01,4,"IBP4, PTEN, IBP, Bcl-2",9.100E-02,7.672E-01,3,"IBP4, IBP, Bcl-2",
54,Apoptosis and survival_HTR1A signaling,50,2.488E-02,4.046E-01,2.798E-02,4.046E-01,4,"PI3K reg class IB (p101), PP2A regulatory, Adenylate cyclase, Bcl-2",2.488E-02,5.522E-01,4,"PI3K reg class IB (p101), PP2A regulatory, Adenylate cyclase, Bcl-2",
55,G-protein signaling_Rap1B regulation pathway,11,2.550E-02,4.046E-01,2.550E-02,4.046E-01,2,"Tuberin, Ca-ATPase3",2.196E-01,8.219E-01,1,Ca-ATPase3,
56,"Development_NCAM1-mediated neurite outgrowth, synapse assembly and neuronal survival",75,2.576E-02,4.046E-01,2.954E-02,4.046E-01,5,"Tau (MAPT), GFRalpha1, NR1, CACNA1H, DNAI1",2.576E-02,5.522E-01,5,"Tau (MAPT), GFRalpha1, NR1, CACNA1H, DNAI1",
57,Regulation of Beta-catenin activity  in melanoma,28,2.610E-02,4.046E-01,2.610E-02,4.046E-01,3,"N-Ras, NRCAM, Bcl-2",1.282E-01,7.672E-01,2,"NRCAM, Bcl-2",
58,Signal transduction_PKA signaling,51,2.654E-02,4.046E-01,2.982E-02,4.046E-01,4,"Androgen receptor, PP2A regulatory, PKI, Adenylate cyclase",2.654E-02,5.522E-01,4,"Androgen receptor, PP2A regulatory, PKI, Adenylate cyclase",
59,Inflammatory factors-induced expression of mucins in normal and asthmatic epithelium,51,2.654E-02,4.046E-01,2.982E-02,4.046E-01,4,"Mucin 5B, IL8RA, Mucin 2, Mucin 5AC",2.654E-02,5.522E-01,4,"Mucin 5B, IL8RA, Mucin 2, Mucin 5AC",
60,Nociception_Nociceptin receptor signaling,76,2.709E-02,4.046E-01,3.105E-02,4.046E-01,5,"TY3H, Kir3.1, AP-2, Adenylate cyclase, Adenylate cyclase type II",2.709E-02,5.522E-01,5,"TY3H, Kir3.1, AP-2, Adenylate cyclase, Adenylate cyclase type II",
61,Neurophysiological process_Leptin signaling in neurons,50,2.798E-02,4.046E-01,2.798E-02,4.046E-01,4,"Kir6.2, PTEN, TY3H, MaxiK alpha subunit",9.992E-02,7.672E-01,3,"Kir6.2, TY3H, MaxiK alpha subunit",
62,Survival pathways in Prostate Cancer,50,2.798E-02,4.046E-01,2.798E-02,4.046E-01,4,"Androgen receptor, PTEN, Tuberin, Bcl-2",3.065E-01,8.219E-01,2,"Androgen receptor, Bcl-2",
63,Signal transduction_Adenosine A2A receptor signaling pathway,52,2.826E-02,4.046E-01,3.174E-02,4.046E-01,4,"Kir6.2, ENPP1, SFK, Adenylate cyclase",2.826E-02,5.522E-01,4,"Kir6.2, ENPP1, SFK, Adenylate cyclase",
64,Neurophysiological process_Mu-type opioid receptor-mediated analgesia,30,2.848E-02,4.046E-01,3.128E-02,4.046E-01,3,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",2.848E-02,5.522E-01,3,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",
65,Development_WNT/Beta-catenin signaling in organogenesis,30,2.848E-02,4.046E-01,3.128E-02,4.046E-01,3,"MEPE, PROP1, FoxN1",2.848E-02,5.522E-01,3,"MEPE, PROP1, FoxN1",
66,Protein folding and maturation_POMC processing,30,2.848E-02,4.046E-01,3.128E-02,4.046E-01,3,"PC2, NAT-1, Carboxypeptidase H",2.848E-02,5.522E-01,3,"PC2, NAT-1, Carboxypeptidase H",
67,Development_Role of BMP signaling in embryonic stem cell neural differentiation,30,2.848E-02,4.046E-01,3.128E-02,4.046E-01,3,"SOX2, Chordin, SOX3",2.848E-02,5.522E-01,3,"SOX2, Chordin, SOX3",
68,Adiponectin in pathogenesis of type 2 diabetes,29,2.863E-02,4.046E-01,2.863E-02,4.046E-01,3,"Adiponectin, FASN, ACACB",1.357E-01,7.984E-01,2,"Adiponectin, ACACB",
69,EGFR family signaling in pancreatic cancer,75,2.954E-02,4.046E-01,2.954E-02,4.046E-01,5,"Tuberin, p27KIP1, N-Ras, Bcl-2, ErbB3",8.163E-01,8.471E-01,1,Bcl-2,
70,Anti-apoptotic action of ErbB2 in breast cancer,51,2.982E-02,4.046E-01,2.982E-02,4.046E-01,4,"Tuberin, p27KIP1, Bcl-2, ErbB3",6.838E-01,8.219E-01,1,Bcl-2,
71,Putative pathways of n-3 and n-6 fatty acids in obesity and type 2 diabetes,51,2.982E-02,4.046E-01,2.982E-02,4.046E-01,4,"Adiponectin, FASN, GPR120, Adenylate cyclase",1.045E-01,7.672E-01,3,"Adiponectin, GPR120, Adenylate cyclase",
72,Regulation of angiogenesis in prostate cancer,51,2.982E-02,4.046E-01,2.982E-02,4.046E-01,4,"Androgen receptor, IL8RA, Tuberin, FOLH1 (GCP2)",1.045E-01,7.672E-01,3,"Androgen receptor, IL8RA, FOLH1 (GCP2)",
73,Aryl hydrocarbon receptor signaling,53,3.005E-02,4.243E-01,3.373E-02,4.243E-01,4,"ESR1 (nuclear), TGM3, TY3H, H-cadherin",3.005E-02,5.697E-01,4,"ESR1 (nuclear), TGM3, TY3H, H-cadherin",
74,Role of adipose tissue hypoxia in obesity and type 2 diabetes,30,3.128E-02,4.046E-01,3.128E-02,4.046E-01,3,"Adiponectin, PDK1, C/EBPalpha",1.434E-01,8.057E-01,2,"Adiponectin, C/EBPalpha",
75,Stem cells_mGluR3 signaling in glioblastoma stem cells,52,3.174E-02,4.046E-01,3.174E-02,4.046E-01,4,"PTEN, SLC1A2/EAAT2, PI3K reg class IB (p101), Adenylate cyclase",1.092E-01,7.672E-01,3,"SLC1A2/EAAT2, PI3K reg class IB (p101), Adenylate cyclase",
76,Androstenedione and testosterone biosynthesis and metabolism p.2,32,3.369E-02,4.472E-01,3.696E-02,4.472E-01,3,"UGT2B28, UGT2B17, UGT2B15",3.369E-02,6.115E-01,3,"UGT2B28, UGT2B17, UGT2B15",
77,Role of ER stress in obesity and type 2 diabetes,54,3.579E-02,4.444E-01,3.579E-02,4.444E-01,4,"Adiponectin, FASN, XBP1, C/EBPalpha",1.187E-01,7.672E-01,3,"Adiponectin, XBP1, C/EBPalpha",
78,Prolactin signaling in Prostate Cancer,33,3.647E-02,4.497E-01,3.998E-02,4.497E-01,3,"Androgen receptor, PIP, Prolactin receptor",3.647E-02,6.221E-01,3,"Androgen receptor, PIP, Prolactin receptor",
79,Cytoskeleton remodeling_Thyroliberin in cytoskeleton remodeling,33,3.647E-02,4.497E-01,3.998E-02,4.497E-01,3,"Adenylate cyclase, Tau (MAPT), Thyroliberin",3.647E-02,6.221E-01,3,"Adenylate cyclase, Tau (MAPT), Thyroliberin",
80,Role of GSK3 beta in cardioprotection against myocardial infarction,33,3.647E-02,4.497E-01,3.998E-02,4.497E-01,3,"Kir6.2, RAMP3, BDKRB2",3.647E-02,6.221E-01,3,"Kir6.2, RAMP3, BDKRB2",
81,Development_Fetal brown fat cell differentiation,55,3.792E-02,4.497E-01,3.792E-02,4.497E-01,4,"FASN, Adenylate cyclase, C/EBPalpha, Prolactin receptor",1.236E-01,7.672E-01,3,"Adenylate cyclase, C/EBPalpha, Prolactin receptor",
82,G-protein signaling_G-Protein beta/gamma signaling cascades,34,3.936E-02,4.739E-01,4.312E-02,4.739E-01,3,"PI3K reg class IB (p101), Adenylate cyclase type V, Adenylate cyclase type II",3.936E-02,6.339E-01,3,"PI3K reg class IB (p101), Adenylate cyclase type V, Adenylate cyclase type II",
83,IL-2 as a growth factor for T cells in multiple sclerosis,33,3.998E-02,4.497E-01,3.998E-02,4.497E-01,3,"Tuberin, p27KIP1, Bcl-2",5.250E-01,8.219E-01,1,Bcl-2,
84,Development_EGF-induced proliferation of Type C cells in SVZ of adult brain,33,3.998E-02,4.497E-01,3.998E-02,4.497E-01,3,"SOX2, p27KIP1, Prolactin receptor",1.669E-01,8.180E-01,2,"SOX2, Prolactin receptor",
85,Transcription_Role of VDR in regulation of genes involved in osteoporosis,59,4.218E-02,4.848E-01,4.716E-02,4.848E-01,4,"PTHR1, Androgen receptor, CG alpha, Calcitonin receptor",4.218E-02,6.339E-01,4,"PTHR1, Androgen receptor, CG alpha, Calcitonin receptor",
86,Production and activation of TGF-beta in airway smooth muscle cells,35,4.236E-02,4.820E-01,4.639E-02,4.820E-01,3,"Tryptase, TGF-beta 3, TGF-beta",4.236E-02,6.339E-01,3,"Tryptase, TGF-beta 3, TGF-beta",
87,Th2-cytokines induced expression of Mucin 5AC and maintenance of mucous cell phenotype in normal airway epithelium,35,4.236E-02,4.820E-01,4.639E-02,4.820E-01,3,"HAG-2, Mucin 5AC, PDEF",4.236E-02,6.339E-01,3,"HAG-2, Mucin 5AC, PDEF",
88,Development_Epigenetic and transcriptional regulation of oligodendrocyte precursor cell differentiation and myelination,34,4.312E-02,4.739E-01,4.312E-02,4.739E-01,3,"Nkx2.2, p27KIP1, MYT1",1.748E-01,8.219E-01,2,"Nkx2.2, MYT1",
89,Th17 cytokines in COPD,36,4.548E-02,4.956E-01,4.977E-02,4.956E-01,3,"Mucin 5B, ROR-gamma, Mucin 5AC",4.548E-02,6.688E-01,3,"Mucin 5B, ROR-gamma, Mucin 5AC",
90,HSP22 and BAG-3-dependend macroautophagy in Huntington's disease,15,4.582E-02,4.820E-01,4.582E-02,4.820E-01,2,"HSP22, Beclin 1",2.869E-01,8.219E-01,1,HSP22,
91,G-protein signaling_S1P2 receptor signaling pathway,35,4.639E-02,4.820E-01,4.639E-02,4.820E-01,3,"PTEN, PI3K reg class IB (p101), Adenylate cyclase",1.829E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
92,Glucose-excited neurons of arcuate nucleus in obesity (rodent model),35,4.639E-02,4.820E-01,4.639E-02,4.820E-01,3,"Kir6.2, Tuberin, SUR1",1.829E-01,8.219E-01,2,"Kir6.2, SUR1",
93,Immune response_IL-9 signaling pathway,61,4.675E-02,5.146E-01,5.221E-02,5.146E-01,4,"Mucin 2, Mucin 5AC, CISH, Bcl-2",4.675E-02,6.758E-01,4,"Mucin 2, Mucin 5AC, CISH, Bcl-2",
94,Regulation of CFTR activity (normal and CF),62,4.913E-02,5.243E-01,5.484E-02,5.243E-01,4,"PDZK1, EBP50, PP2A regulatory, Adenylate cyclase",4.913E-02,6.870E-01,4,"PDZK1, EBP50, PP2A regulatory, Adenylate cyclase",
95,Regulation of intrinsic membrane properties and excitability of striatonigral medium spiny neurons in Huntington's disease,62,4.913E-02,5.243E-01,5.484E-02,5.243E-01,4,"MaxiK alpha subunit, Adenylate cyclase type V, PDE1B, CACNA1D",4.913E-02,6.870E-01,4,"MaxiK alpha subunit, Adenylate cyclase type V, PDE1B, CACNA1D",
96,Signal transduction_mTORC1 downstream signaling,60,4.965E-02,4.956E-01,4.965E-02,4.956E-01,4,"PDK1, p27KIP1, PDCD4, HMGCS2",3.876E-01,8.219E-01,2,"PDCD4, HMGCS2",
97,IGF family signaling in colorectal cancer,60,4.965E-02,4.956E-01,4.965E-02,4.956E-01,4,"PTEN, IBP, C/EBPalpha, Clusterin",1.492E-01,8.057E-01,3,"IBP, C/EBPalpha, Clusterin",
98,Signal transduction_Cyclic AMP signaling,38,5.204E-02,5.279E-01,5.688E-02,5.279E-01,3,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",5.204E-02,6.935E-01,3,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",
99,Defective efferocytosis in COPD,38,5.204E-02,5.279E-01,5.688E-02,5.279E-01,3,"SP-D, CX3CR1, ELMO1",5.204E-02,6.935E-01,3,"SP-D, CX3CR1, ELMO1",
100,"Dysregulation of Adiponectin secretion from adipocytes in obesity, type 2 diabetes and metabolic syndrome X",38,5.204E-02,5.279E-01,5.688E-02,5.279E-01,3,"Adiponectin, C/EBPalpha, AP-2B",5.204E-02,6.935E-01,3,"Adiponectin, C/EBPalpha, AP-2B",
101,"Immune response_IL-4-induced regulators of cell growth, survival, differentiation and metabolism",62,5.484E-02,5.243E-01,5.484E-02,5.243E-01,4,"GATA-3, p27KIP1, CISH, Bcl-2",1.598E-01,8.180E-01,3,"GATA-3, CISH, Bcl-2",
102,PXR-mediated direct regulation of xenobiotic metabolizing enzymes / Rodent version,39,5.548E-02,5.452E-01,6.061E-02,5.452E-01,3,"S14 protein, CYP2B6, OATP-A",5.548E-02,7.280E-01,3,"S14 protein, CYP2B6, OATP-A",
103,Neurophysiological process_Constitutive and regulated NMDA receptor trafficking,65,5.668E-02,5.452E-01,6.315E-02,5.452E-01,4,"Chapsyn-110, Adenylate cyclase, NR1, MALS",5.668E-02,7.326E-01,4,"Chapsyn-110, Adenylate cyclase, NR1, MALS",
104,Apoptosis and survival_CXCR3-B signaling,63,5.754E-02,5.289E-01,5.754E-02,5.289E-01,4,"GATA-3, Adenylate cyclase, Bcl-2, Beclin 1",1.652E-01,8.180E-01,3,"GATA-3, Adenylate cyclase, Bcl-2",
105,Reproduction_Progesterone-mediated oocyte maturation,40,5.903E-02,5.452E-01,6.445E-02,5.452E-01,3,"ESR1 (membrane), Adenylate cyclase, PR (membrane)",5.903E-02,7.404E-01,3,"ESR1 (membrane), Adenylate cyclase, PR (membrane)",
106,Cell adhesion_IL-8 family-dependent cell migration and adhesion,40,5.903E-02,5.452E-01,6.445E-02,5.452E-01,3,"IL8RA, PI3K reg class IB (p101), EBP50",5.903E-02,7.404E-01,3,"IL8RA, PI3K reg class IB (p101), EBP50",
107,"Development_The role of GDNF ligand family/ RET receptor in cell survival, growth and proliferation",92,6.175E-02,5.452E-01,6.175E-02,5.452E-01,5,"GFRalpha2, N-Ras, Dopamine transporter, GFRalpha1, Bcl-2",1.492E-01,8.057E-01,4,"GFRalpha2, Dopamine transporter, GFRalpha1, Bcl-2",
108,Ovarian cancer (main signaling cascades),65,6.315E-02,5.452E-01,6.315E-02,5.452E-01,4,"ESR1 (nuclear), Androgen receptor, PTEN, PI3K reg class IB (p101)",1.762E-01,8.219E-01,3,"ESR1 (nuclear), Androgen receptor, PI3K reg class IB (p101)",
109,Neurophysiological process_Glucose-excited neurons of arcuate nucleus (rodent model),40,6.445E-02,5.452E-01,6.445E-02,5.452E-01,3,"Kir6.2, Tuberin, SUR1",2.237E-01,8.219E-01,2,"Kir6.2, SUR1",
110,IL-6 signaling in Prostate Cancer,40,6.445E-02,5.452E-01,6.445E-02,5.452E-01,3,"Androgen receptor, PTEN, p27KIP1",5.944E-01,8.219E-01,1,Androgen receptor,
111,Inhibition of Vitamin D pathway in Prostate Cancer,40,6.445E-02,5.452E-01,6.445E-02,5.452E-01,3,"Androgen receptor, p27KIP1, Bcl-2",2.237E-01,8.219E-01,2,"Androgen receptor, Bcl-2",
112,Anti-apoptotic pathways in endoplasmic reticulum stress response in multiple myeloma,19,6.591E-02,5.522E-01,7.028E-02,5.522E-01,2,"XBP1, Bcl-2",6.591E-02,7.539E-01,2,"XBP1, Bcl-2",
113,Brca1 and Brca2 in breast cancer,19,6.591E-02,5.522E-01,7.028E-02,5.522E-01,2,"ESR1 (nuclear), ESR1 (membrane)",6.591E-02,7.539E-01,2,"ESR1 (nuclear), ESR1 (membrane)",
114,Transcription_HIF-1 targets,95,6.891E-02,5.522E-01,6.891E-02,5.522E-01,5,"PDK1, SOX2, TGF-beta 3, CX3CR1, Carbonic anhydrase XII",1.618E-01,8.180E-01,4,"SOX2, TGF-beta 3, CX3CR1, Carbonic anhydrase XII",
115,Development_Alpha-1 adrenergic receptors signaling via Cyclic AMP,19,7.028E-02,5.522E-01,7.028E-02,5.522E-01,2,"p27KIP1, Adenylate cyclase",3.484E-01,8.219E-01,1,Adenylate cyclase,
116,Th2-cytokines-induced expression of mucins in asthma ,43,7.029E-02,5.522E-01,7.661E-02,5.522E-01,3,"Mucin 5B, Mucin 2, Mucin 5AC",7.029E-02,7.539E-01,3,"Mucin 5B, Mucin 2, Mucin 5AC",
117,"Chemotaxis_CCL16-, CCL20-, CXCL16- and CCL25-mediated cell migration",43,7.029E-02,5.522E-01,7.661E-02,5.522E-01,3,"PI3K reg class IB (p101), CCR8, CCR5",7.029E-02,7.539E-01,3,"PI3K reg class IB (p101), CCR8, CCR5",
118,Neurophysiological process_HTR1A receptor signaling in neuronal cells,43,7.029E-02,5.522E-01,7.661E-02,5.522E-01,3,"Kir3.1, PI3K reg class IB (p101), Adenylate cyclase",7.029E-02,7.539E-01,3,"Kir3.1, PI3K reg class IB (p101), Adenylate cyclase",
119,Tyrosine metabolism p.1 (dopamine) ,70,7.056E-02,5.522E-01,7.838E-02,5.522E-01,4,"TY3H, PNMT, ABP1, PAH",7.056E-02,7.539E-01,4,"TY3H, PNMT, ABP1, PAH",
120,Th2-cytokine-induced airway epithelium mucous metaplasia in COPD,70,7.056E-02,5.522E-01,7.838E-02,5.522E-01,4,"HAG-2, PP2A regulatory, Mucin 5AC, PDEF",7.056E-02,7.539E-01,4,"HAG-2, PP2A regulatory, Mucin 5AC, PDEF",
121,Neurophysiological process_Olfactory transduction,20,7.219E-02,5.522E-01,7.693E-02,5.522E-01,2,"Olfactory receptor, ANO2",7.219E-02,7.539E-01,2,"Olfactory receptor, ANO2",
122,PR action in breast cancer: stimulation of metastasis,20,7.219E-02,5.522E-01,7.693E-02,5.522E-01,2,"PR (membrane), PR (nuclear)",7.219E-02,7.539E-01,2,"PR (membrane), PR (nuclear)",
123,Protein folding and maturation_Insulin processing,20,7.219E-02,5.522E-01,7.693E-02,5.522E-01,2,"PC2, Carboxypeptidase H",7.219E-02,7.539E-01,2,"PC2, Carboxypeptidase H",
124,Serotonin modulation of dopamine release in nicotine addiction,42,7.245E-02,5.522E-01,7.245E-02,5.522E-01,3,"PTEN, Adenylate cyclase, nAChR alpha-4",2.402E-01,8.219E-01,2,"Adenylate cyclase, nAChR alpha-4",
125,Growth factors in regulation of oligodendrocyte precursor cells survival in multiple sclerosis,42,7.245E-02,5.522E-01,7.245E-02,5.522E-01,3,"IBP, Bcl-2, ErbB3",2.402E-01,8.219E-01,2,"IBP, Bcl-2",
126,Immune response_PIP3 signaling in B lymphocytes,42,7.245E-02,5.522E-01,7.245E-02,5.522E-01,3,"PTEN, PI3K reg class IB (p101), PREX1",2.402E-01,8.219E-01,2,"PI3K reg class IB (p101), PREX1",
127,Inhibition of neutrophil migration by proresolving lipid mediators in COPD,71,7.353E-02,5.535E-01,8.163E-02,5.535E-01,4,"IL8RA, PI3K reg class IB (p101), CCR5, PREX1",7.353E-02,7.539E-01,4,"IL8RA, PI3K reg class IB (p101), CCR5, PREX1",
128,Neurophysiological process_Melatonin signaling,44,7.424E-02,5.522E-01,8.087E-02,5.522E-01,3,"Kir3.1, MaxiK alpha subunit, Adenylate cyclase",7.424E-02,7.539E-01,3,"Kir3.1, MaxiK alpha subunit, Adenylate cyclase",
129,Role of CD8+ Tc1 cells in COPD,44,7.424E-02,5.522E-01,8.087E-02,5.522E-01,3,"CX3CR1, CCR5, Bcl-2",7.424E-02,7.539E-01,3,"CX3CR1, CCR5, Bcl-2",
130,Transport_cAMP/ Ca(2+)-dependent Insulin secretion,44,7.424E-02,5.522E-01,8.087E-02,5.522E-01,3,"Kir6.2, SUR1, CACNA1D",7.424E-02,7.539E-01,3,"Kir6.2, SUR1, CACNA1D",
131,Mucin expression in CF airways,69,7.520E-02,5.522E-01,7.520E-02,5.522E-01,4,"Mucin 5B, Mucin 2, Mucin 5AC, ErbB3",1.988E-01,8.219E-01,3,"Mucin 5B, Mucin 2, Mucin 5AC",
132,Translation_Non-genomic (rapid) action of Androgen Receptor,43,7.661E-02,5.522E-01,7.661E-02,5.522E-01,3,"Androgen receptor, PTEN, Tuberin",6.210E-01,8.219E-01,1,Androgen receptor,
133,FGF signaling in Prostate Cancer,43,7.661E-02,5.522E-01,7.661E-02,5.522E-01,3,"Androgen receptor, PTEN, FGFR4",2.485E-01,8.219E-01,2,"Androgen receptor, FGFR4",
134,Cell adhesion_Ephrin signaling,45,7.829E-02,5.698E-01,8.524E-02,5.698E-01,3,"Ephrin-A receptor 8, Ephrin-A receptors, RHO6",7.829E-02,7.672E-01,3,"Ephrin-A receptor 8, Ephrin-A receptors, RHO6",
135,Hypertrophy of  asthmatic airway smooth muscle cells ,70,7.838E-02,5.522E-01,7.838E-02,5.522E-01,4,"TGF-beta 3, Tuberin, LIN-28, C/EBPalpha",2.045E-01,8.219E-01,3,"TGF-beta 3, LIN-28, C/EBPalpha",
136,SLE genetic marker-specific pathways in B cells,99,7.914E-02,5.522E-01,7.914E-02,5.522E-01,5,"p27KIP1, XBP1, BANK, Bcl-2, BLNK",1.792E-01,8.219E-01,4,"XBP1, BANK, Bcl-2, BLNK",
137,Regulation of metabolism_Triiodothyronine and Thyroxine signaling,44,8.087E-02,5.522E-01,8.087E-02,5.522E-01,3,"S14 protein, FASN, DIO1",2.568E-01,8.219E-01,2,"S14 protein, DIO1",
138,IGF signaling in lung cancer,44,8.087E-02,5.522E-01,8.087E-02,5.522E-01,3,"IBP4, Tuberin, IBP",2.568E-01,8.219E-01,2,"IBP4, IBP",
139,K-RAS signaling in pancreatic cancer,44,8.087E-02,5.522E-01,8.087E-02,5.522E-01,3,"PTEN, FGFR4, Bcl-2",2.568E-01,8.219E-01,2,"FGFR4, Bcl-2",
140,Neurophysiological process_Receptor-mediated axon growth repulsion,46,8.244E-02,5.865E-01,8.970E-02,5.865E-01,3,"Ephrin-A receptors, Tau (MAPT), RHO6",8.244E-02,7.672E-01,3,"Ephrin-A receptors, Tau (MAPT), RHO6",
141,Development_Membrane-bound ESR1: interaction with growth factors signaling,45,8.524E-02,5.698E-01,8.524E-02,5.698E-01,3,"ESR1 (nuclear), ESR1 (membrane), ErbB3",2.651E-01,8.219E-01,2,"ESR1 (nuclear), ESR1 (membrane)",
142,Amitraz-induced inhibition of Insulin secretion,22,8.529E-02,5.865E-01,9.080E-02,5.865E-01,2,"Adenylate cyclase type V, Alpha-2A adrenergic receptor",8.529E-02,7.672E-01,2,"Adenylate cyclase type V, Alpha-2A adrenergic receptor",
143,T regulatory cell migration in asthma,22,8.529E-02,5.865E-01,9.080E-02,5.865E-01,2,"PI3K reg class IB (p101), CCR8",8.529E-02,7.672E-01,2,"PI3K reg class IB (p101), CCR8",
144,Mechanism of Maraviroc action in HIV Infections,4,8.617E-02,5.865E-01,8.928E-02,5.865E-01,1,CCR5,8.617E-02,7.672E-01,1,CCR5,
145,Inhibition of RUNX3 signaling in gastric cancer,22,9.080E-02,5.865E-01,9.080E-02,5.865E-01,2,"p27KIP1, Bcl-2",3.910E-01,8.219E-01,1,Bcl-2,
146,Common mechanisms of Th17 cell migration,48,9.100E-02,6.023E-01,9.891E-02,6.023E-01,3,"PI3K reg class IB (p101), Collagen II, CCR5",9.100E-02,7.672E-01,3,"PI3K reg class IB (p101), Collagen II, CCR5",
147,IL-17-induced mucin expression in CF airways,48,9.100E-02,6.023E-01,9.891E-02,6.023E-01,3,"Mucin 5B, ROR-gamma, Mucin 5AC",9.100E-02,7.672E-01,3,"Mucin 5B, ROR-gamma, Mucin 5AC",
148,Oxidative stress_Role of IL-8 signaling pathway in respiratory burst,48,9.100E-02,6.023E-01,9.891E-02,6.023E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",9.100E-02,7.672E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",
149,Action of GSK3 beta in bipolar disorder,23,9.209E-02,6.023E-01,9.798E-02,6.023E-01,2,"Tau (MAPT), Bcl-2",9.209E-02,7.672E-01,2,"Tau (MAPT), Bcl-2",
150,Development_Thrombopoietin signaling via JAK-STAT pathway,23,9.209E-02,6.023E-01,9.798E-02,6.023E-01,2,"ERG, CISH",9.209E-02,7.672E-01,2,"ERG, CISH",
151,Development_TGF-beta-dependent induction of EMT via MAPK ,47,9.426E-02,6.007E-01,9.426E-02,6.007E-01,3,"PTEN, TGF-beta 3, TGF-beta",2.817E-01,8.219E-01,2,"TGF-beta 3, TGF-beta",
152,Development_PIP3 signaling in cardiac myocytes,47,9.426E-02,6.007E-01,9.426E-02,6.007E-01,3,"PTEN, Tuberin, PI3K reg class IB (p101)",6.538E-01,8.219E-01,1,PI3K reg class IB (p101),
153,Regulation of lipid metabolism_Regulation of lipid metabolism by niacin and isoprenaline,49,9.542E-02,6.177E-01,1.036E-01,6.177E-01,3,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",9.542E-02,7.672E-01,3,"Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",
154,Transcription_N-CoR/ SMRT complex-mediated epigenetic gene silencing,49,9.542E-02,6.177E-01,1.036E-01,6.177E-01,3,"PBX1, HOXB1, PBX1a/HOXB1",9.542E-02,7.672E-01,3,"PBX1, HOXB1, PBX1a/HOXB1",
155,Translation_Opioid receptors in regulation of translation ,23,9.798E-02,6.023E-01,9.798E-02,6.023E-01,2,"Tuberin, PI3K reg class IB (p101)",4.046E-01,8.219E-01,1,PI3K reg class IB (p101),
156,K-RAS signaling in lung cancer,48,9.891E-02,6.023E-01,9.891E-02,6.023E-01,3,"PTEN, RhoB, PDCD4",2.900E-01,8.219E-01,2,"RhoB, PDCD4",
157,Development_Schema: SMAD-dependent TGF-beta family signaling in embryonic stem cells,24,9.904E-02,6.177E-01,1.053E-01,6.177E-01,2,"SOX2, MSX-2",9.904E-02,7.672E-01,2,"SOX2, MSX-2",
158,Prolactin/ JAK2 signaling in breast cancer,24,9.904E-02,6.177E-01,1.053E-01,6.177E-01,2,"CISH, Prolactin receptor",9.904E-02,7.672E-01,2,"CISH, Prolactin receptor",
159,Huntingtin-depended transcription deregulation in Huntington's Disease,24,9.904E-02,6.177E-01,1.053E-01,6.177E-01,2,"NR1, C/EBPalpha",9.904E-02,7.672E-01,2,"NR1, C/EBPalpha",
160,Signal transduction_CXCR4 signaling via second messengers and JAK/STAT,50,9.992E-02,6.195E-01,1.085E-01,6.195E-01,3,"MaxiK alpha subunit, Adenylate cyclase, Bcl-2",9.992E-02,7.672E-01,3,"MaxiK alpha subunit, Adenylate cyclase, Bcl-2",
161,Immune response_Inhibitory action of lipoxins on superoxide production induced by IL-8 and Leukotriene B4 in neutrophils,50,9.992E-02,6.195E-01,1.085E-01,6.195E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",9.992E-02,7.672E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",
162,Development_Signaling pathways in embryonic hepatocyte maturation,51,1.045E-01,6.195E-01,1.134E-01,6.195E-01,3,"TAT, PAH, C/EBPalpha",1.045E-01,7.672E-01,3,"TAT, PAH, C/EBPalpha",
163,Tissue factor signaling in lung cancer,24,1.053E-01,6.177E-01,1.053E-01,6.177E-01,2,"PTEN, Coagulation factor VII",4.179E-01,8.219E-01,1,Coagulation factor VII,
164,Development_Trophectoderm differentiation,25,1.061E-01,6.195E-01,1.128E-01,6.195E-01,2,"SOX2, ASH2",1.061E-01,7.672E-01,2,"SOX2, ASH2",
165,Defective macrophage-mediated bacterial phagocytosis in COPD,25,1.061E-01,6.195E-01,1.128E-01,6.195E-01,2,"RhoB, SP-D",1.061E-01,7.672E-01,2,"RhoB, SP-D",
166,Fenofibrate in treatment of type 2 diabetes and metabolic syndrome X,25,1.061E-01,6.195E-01,1.128E-01,6.195E-01,2,"Adiponectin, ABCG1",1.061E-01,7.672E-01,2,"Adiponectin, ABCG1",
167,Inhibition of TGF-beta signaling in gastric cancer,25,1.061E-01,6.195E-01,1.128E-01,6.195E-01,2,"CEACAM5, TGF-beta 3",1.061E-01,7.672E-01,2,"CEACAM5, TGF-beta 3",
168,Possible role of neonatal nicotine exposure in development of postnatal obesity,5,1.065E-01,6.195E-01,1.103E-01,6.195E-01,1,nAChR alpha-4,1.065E-01,7.672E-01,1,nAChR alpha-4,
169,The role of PTEN and PI3K signaling in melanoma,50,1.085E-01,6.195E-01,1.085E-01,6.195E-01,3,"PTEN, N-Ras, Tau (MAPT)",6.765E-01,8.219E-01,1,Tau (MAPT),
170,HBV-dependent NF-kB and PI3K/AKT pathways leading to HCC,50,1.085E-01,6.195E-01,1.085E-01,6.195E-01,3,"Androgen receptor, PTEN, p27KIP1",6.765E-01,8.219E-01,1,Androgen receptor,
171,Gamma-aminobutyrate (GABA) biosynthesis and metabolism,52,1.092E-01,6.306E-01,1.184E-01,6.306E-01,3,"GABT, ABP1, DHE4",1.092E-01,7.672E-01,3,"GABT, ABP1, DHE4",
172,HBV-dependent transcription regulation leading to HCC,25,1.128E-01,6.195E-01,1.128E-01,6.195E-01,2,"ESR1 (nuclear), FASN",4.309E-01,8.219E-01,1,ESR1 (nuclear),
173,CAR signaling via cross-talk / Human Version,26,1.133E-01,6.306E-01,1.204E-01,6.306E-01,2,"ESR1 (nuclear), CYP2B6",1.133E-01,7.672E-01,2,"ESR1 (nuclear), CYP2B6",
174,Role of fibroblasts and keratinocytes in the elicitation phase of allergic contact dermatitis,26,1.133E-01,6.306E-01,1.204E-01,6.306E-01,2,"IL8RA, CCR5",1.133E-01,7.672E-01,2,"IL8RA, CCR5",
175,Neurophysiological process_Dopamine D2 receptor transactivation of PDGFR in CNS,26,1.133E-01,6.306E-01,1.204E-01,6.306E-01,2,"PP2A regulatory, NR1",1.133E-01,7.672E-01,2,"PP2A regulatory, NR1",
176,Pioglitazone and Rosiglitazone in treatment of type 2 diabetes and metabolic syndrome X,26,1.133E-01,6.306E-01,1.204E-01,6.306E-01,2,"Adiponectin, ABCG1",1.133E-01,7.672E-01,2,"Adiponectin, ABCG1",
177,Glyoxylate metabolism,26,1.133E-01,6.306E-01,1.204E-01,6.306E-01,2,"AGT2, AGXT",1.133E-01,7.672E-01,2,"AGT2, AGXT",
178,microRNA in Prostate Cancer,51,1.134E-01,6.195E-01,1.134E-01,6.195E-01,3,"p27KIP1, PDCD4, Bcl-2",3.148E-01,8.219E-01,2,"PDCD4, Bcl-2",
179,Immune response_Alternative complement pathway,53,1.139E-01,6.306E-01,1.235E-01,6.306E-01,3,"FHR-5, C5L2, Clusterin",1.139E-01,7.672E-01,3,"FHR-5, C5L2, Clusterin",
180,Chemotaxis_Inhibitory action of lipoxins on IL-8- and Leukotriene B4-induced neutrophil migration,53,1.139E-01,6.306E-01,1.235E-01,6.306E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",1.139E-01,7.672E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",
181,Dysregulation of indirect glucose-induced inhibition of Glucagon secretion from alpha-cells in type 2 diabetes ,54,1.187E-01,6.306E-01,1.286E-01,6.306E-01,3,"Kir6.2, PC2, SUR1",1.187E-01,7.672E-01,3,"Kir6.2, PC2, SUR1",
182,GTP metabolism,54,1.187E-01,6.306E-01,1.286E-01,6.306E-01,3,"GUCY1B2, Guanylate cyclase beta, PDE1B",1.187E-01,7.672E-01,3,"GUCY1B2, Guanylate cyclase beta, PDE1B",
183,Impaired inhibitory action of lipoxins on ROS production in neutrophils in CF,54,1.187E-01,6.306E-01,1.286E-01,6.306E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",1.187E-01,7.672E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",
184,CAR signaling via cross-talk / Rodent version,27,1.207E-01,6.306E-01,1.282E-01,6.306E-01,2,"ESR1 (nuclear), CYP2B6",1.207E-01,7.672E-01,2,"ESR1 (nuclear), CYP2B6",
185,Glomerular filtration and renal reabsorption of bile acids / Rodent version,27,1.207E-01,6.306E-01,1.282E-01,6.306E-01,2,"ABCC11, OATP-A",1.207E-01,7.672E-01,2,"ABCC11, OATP-A",
186,Development_Generation of pancreatic beta-cells from induced pluripotent stem cells,27,1.207E-01,6.306E-01,1.282E-01,6.306E-01,2,"Nkx2.2, SOX2",1.207E-01,7.672E-01,2,"Nkx2.2, SOX2",
187,Neurophysiological process_Sweet taste signaling,27,1.207E-01,6.306E-01,1.282E-01,6.306E-01,2,"P2X2, TRPM5",1.207E-01,7.672E-01,2,"P2X2, TRPM5",
188,Epigenetic alterations in ovarian cancer,82,1.215E-01,6.306E-01,1.215E-01,6.306E-01,4,"ESR1 (nuclear), H-cadherin, p27KIP1, Gamma-synuclein",2.758E-01,8.219E-01,3,"ESR1 (nuclear), H-cadherin, Gamma-synuclein",
189,Immune response_Inhibitory PD-1 signaling in T cells,53,1.235E-01,6.306E-01,1.235E-01,6.306E-01,3,"PTEN, GATA-3, p27KIP1",6.977E-01,8.219E-01,1,GATA-3,
190,Non-genomic signaling of ESR2 (membrane) in lung cancer cells,53,1.235E-01,6.306E-01,1.235E-01,6.306E-01,3,"N-Ras, Adenylate cyclase, nAChR alpha-4",3.312E-01,8.219E-01,2,"Adenylate cyclase, nAChR alpha-4",
191,EGFR signaling pathway in lung cancer,53,1.235E-01,6.306E-01,1.235E-01,6.306E-01,3,"PTEN, Bcl-2, ErbB3",6.977E-01,8.219E-01,1,Bcl-2,
192,Cell adhesion_ECM remodeling,55,1.236E-01,6.427E-01,1.339E-01,6.427E-01,3,"IBP4, IL8RA, Collagen II",1.236E-01,7.672E-01,3,"IBP4, IL8RA, Collagen II",
193,Basophil migration in asthma,55,1.236E-01,6.427E-01,1.339E-01,6.427E-01,3,"FPRL2, IL8RA, PI3K reg class IB (p101)",1.236E-01,7.672E-01,3,"FPRL2, IL8RA, PI3K reg class IB (p101)",
194,Proteases and EGFR-induced mucin synthesis in normal and asthmatic epithelium,55,1.236E-01,6.427E-01,1.339E-01,6.427E-01,3,"Mucin 5B, Mucin 2, Mucin 5AC",1.236E-01,7.672E-01,3,"Mucin 5B, Mucin 2, Mucin 5AC",
195,Impaired inhibition of Th17 cell differentiation by IFN-beta in multiple sclerosis,28,1.282E-01,6.427E-01,1.360E-01,6.427E-01,2,"ROR-gamma, IL-30",1.282E-01,7.672E-01,2,"ROR-gamma, IL-30",
196,Role of Diethylhexyl Phthalate and Tributyltin in fat cell differentiation ,28,1.282E-01,6.427E-01,1.360E-01,6.427E-01,2,"Adiponectin, C/EBPalpha",1.282E-01,7.672E-01,2,"Adiponectin, C/EBPalpha",
197,GLP-1 in inhibition of insulin secretion in type 2 diabetes,28,1.282E-01,6.427E-01,1.360E-01,6.427E-01,2,"Kir6.2, CACNA1D",1.282E-01,7.672E-01,2,"Kir6.2, CACNA1D",
198,Neurophysiological process_Bitter taste signaling,28,1.282E-01,6.427E-01,1.360E-01,6.427E-01,2,"P2X2, TRPM5",1.282E-01,7.672E-01,2,"P2X2, TRPM5",
199,Nicotine metabolism in liver,56,1.286E-01,6.427E-01,1.392E-01,6.427E-01,3,"CYP2A6, CYP2B6, INMT",1.286E-01,7.672E-01,3,"CYP2A6, CYP2B6, INMT",
200,Immune response_IL-5 signaling via JAK/STAT,56,1.286E-01,6.427E-01,1.392E-01,6.427E-01,3,"XBP1, CISH, Bcl-2",1.286E-01,7.672E-01,3,"XBP1, CISH, Bcl-2",
201,Impaired inhibitory action of lipoxins on neutrophil migration in CF,56,1.286E-01,6.427E-01,1.392E-01,6.427E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",1.286E-01,7.672E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",
202,Regulation of AKT(PKB)/ GSK3 beta cascade in bipolar disorder,54,1.286E-01,6.306E-01,1.286E-01,6.306E-01,3,"PTEN, ESR1 (membrane), GFRalpha1",3.393E-01,8.219E-01,2,"ESR1 (membrane), GFRalpha1",
203,Pro-oncogenic action of PTHrP in breast cancer,29,1.357E-01,6.549E-01,1.440E-01,6.549E-01,2,"PTHR1, Bcl-2",1.357E-01,7.984E-01,2,"PTHR1, Bcl-2",
204,Regulation of Beta-catenin activity in colorectal cancer,56,1.392E-01,6.427E-01,1.392E-01,6.427E-01,3,"PTEN, PDCD4, Adenylate cyclase",3.556E-01,8.219E-01,2,"PDCD4, Adenylate cyclase",
205,Development_Transcription factors in segregation of hepatocytic lineage,30,1.434E-01,6.636E-01,1.520E-01,6.636E-01,2,"Alpha 1-antitrypsin, C/EBPalpha",1.434E-01,8.057E-01,2,"Alpha 1-antitrypsin, C/EBPalpha",
206,Role of prenatal nicotine exposure in apoptosis and proliferation of pancreatic beta cells,30,1.434E-01,6.636E-01,1.520E-01,6.636E-01,2,"Bcl-2, nAChR alpha-4",1.434E-01,8.057E-01,2,"Bcl-2, nAChR alpha-4",
207,Transcription_Ligand-dependent activation of the ESR1/SP pathway,30,1.434E-01,6.636E-01,1.520E-01,6.636E-01,2,"ESR1 (nuclear), Prolactin receptor",1.434E-01,8.057E-01,2,"ESR1 (nuclear), Prolactin receptor",
208,Inhibition of Ephrin receptors in colorectal cancer,30,1.434E-01,6.636E-01,1.520E-01,6.636E-01,2,"Ephrin-A receptor 7, Ephrin-A receptors",1.434E-01,8.057E-01,2,"Ephrin-A receptor 7, Ephrin-A receptors",
209,Putative pathways of Oleic acid sensing in ventromedial hypothalamus in obesity (rodent model),30,1.434E-01,6.636E-01,1.520E-01,6.636E-01,2,"Kir6.2, SUR1",1.434E-01,8.057E-01,2,"Kir6.2, SUR1",
210,Apoptosis and survival_nAChR in apoptosis inhibition and cell cycle progression,29,1.440E-01,6.549E-01,1.440E-01,6.549E-01,2,"Tuberin, nAChR alpha",4.800E-01,8.219E-01,1,nAChR alpha,
211,Development_Auditory hair cell differentiation in embryogenesis,29,1.440E-01,6.549E-01,1.440E-01,6.549E-01,2,"SOX2, p27KIP1",4.800E-01,8.219E-01,1,SOX2,
212,MicroRNAs in melanoma,57,1.445E-01,6.549E-01,1.445E-01,6.549E-01,3,"p27KIP1, MaxiK alpha subunit, N-Ras",7.239E-01,8.222E-01,1,MaxiK alpha subunit,
213,Signal transduction_MIF signaling pathway,60,1.492E-01,6.783E-01,1.611E-01,6.783E-01,3,"SFK, PI3K reg class IB (p101), Bcl-2",1.492E-01,8.057E-01,3,"SFK, PI3K reg class IB (p101), Bcl-2",
214,Development_Thyroliberin signaling,60,1.492E-01,6.783E-01,1.611E-01,6.783E-01,3,"CG alpha, Adenylate cyclase, Thyroliberin",1.492E-01,8.057E-01,3,"CG alpha, Adenylate cyclase, Thyroliberin",
215,Pro-oncogenic action of Estradiol/ Estrogen receptors in ovarian cancer,60,1.492E-01,6.783E-01,1.611E-01,6.783E-01,3,"ESR1 (nuclear), TFF1, ESR1 (membrane)",1.492E-01,8.057E-01,3,"ESR1 (nuclear), TFF1, ESR1 (membrane)",
216,Neurophysiological process_Kappa-type opioid receptor in transmission of nerve impulses,31,1.511E-01,6.783E-01,1.601E-01,6.783E-01,2,"Kir3.1, EBP50",1.511E-01,8.057E-01,2,"Kir3.1, EBP50",
217,Development_FGF and BMP signaling in early embryonic hepatogenesis,31,1.511E-01,6.783E-01,1.601E-01,6.783E-01,2,"HNF3-alpha, FGFR4",1.511E-01,8.057E-01,2,"HNF3-alpha, FGFR4",
218,Regulation of lipid metabolism_FXR-dependent negative-feedback regulation of bile acids concentration,31,1.511E-01,6.783E-01,1.601E-01,6.783E-01,2,"HNF3-alpha, CYP2B6",1.511E-01,8.057E-01,2,"HNF3-alpha, CYP2B6",
219,Linoleic acid metabolism,31,1.511E-01,6.783E-01,1.601E-01,6.783E-01,2,"PLA2(hGIIA), ALOX15B",1.511E-01,8.057E-01,2,"PLA2(hGIIA), ALOX15B",
220,DNA damage_Brca1 as a transcription regulator,30,1.520E-01,6.636E-01,1.520E-01,6.636E-01,2,"ESR1 (nuclear), p27KIP1",4.917E-01,8.219E-01,1,ESR1 (nuclear),
221,Development_G-CSF-induced myeloid differentiation,30,1.520E-01,6.636E-01,1.520E-01,6.636E-01,2,"p27KIP1, C/EBPalpha",4.917E-01,8.219E-01,1,C/EBPalpha,
222,"Immune response_IL-3 signaling via JAK/STAT, p38, JNK and NF-kB",93,1.533E-01,6.908E-01,1.681E-01,6.908E-01,4,"TCR gamma locus, XBP1, CISH, Bcl-2",1.533E-01,8.124E-01,4,"TCR gamma locus, XBP1, CISH, Bcl-2",
223,Role of IL-6 in obesity and type 2 diabetes in adipocytes,32,1.590E-01,6.908E-01,1.684E-01,6.908E-01,2,"Adiponectin, Perilipin",1.590E-01,8.180E-01,2,"Adiponectin, Perilipin",
224,Neurophysiological process_Glucose-excited neurons of ventromedial nucleus (rodent model),32,1.590E-01,6.908E-01,1.684E-01,6.908E-01,2,"Kir6.2, SUR1",1.590E-01,8.180E-01,2,"Kir6.2, SUR1",
225,Heparan sulfate/heparin metabolism,62,1.598E-01,7.008E-01,1.724E-01,7.008E-01,3,"3-OST5, HSST4, HS6ST3",1.598E-01,8.180E-01,3,"3-OST5, HSST4, HS6ST3",
226,Mechanisms of K-RAS addiction in lung cancer cells,31,1.601E-01,6.783E-01,1.601E-01,6.783E-01,2,"PTEN, Bcl-2",5.030E-01,8.219E-01,1,Bcl-2,
227,Degranulation of lung mast cells,63,1.652E-01,7.008E-01,1.781E-01,7.008E-01,3,"Tryptase, PGE2R3, BDKRB2",1.652E-01,8.180E-01,3,"Tryptase, PGE2R3, BDKRB2",
228,O-glycan biosynthesis,63,1.652E-01,7.008E-01,1.781E-01,7.008E-01,3,"GALNT6, GALNTL1, GALNTL3",1.652E-01,8.180E-01,3,"GALNT6, GALNTL1, GALNTL3",
229,Neuroprotective action of lithium,63,1.652E-01,7.008E-01,1.781E-01,7.008E-01,3,"P2X2, Tau (MAPT), Bcl-2",1.652E-01,8.180E-01,3,"P2X2, Tau (MAPT), Bcl-2",
230,Development_BMP signaling,33,1.669E-01,7.008E-01,1.766E-01,7.008E-01,2,"Chordin, Tob1",1.669E-01,8.180E-01,2,"Chordin, Tob1",
231,Nicotine signaling in glutamatergic neurons,33,1.669E-01,7.008E-01,1.766E-01,7.008E-01,2,"Adenylate cyclase type V, nAChR alpha-4",1.669E-01,8.180E-01,2,"Adenylate cyclase type V, nAChR alpha-4",
232,Muscle contraction_Role of kappa-type opioid receptor in heart,33,1.669E-01,7.008E-01,1.766E-01,7.008E-01,2,"Kir6.2, Adenylate cyclase",1.669E-01,8.180E-01,2,"Kir6.2, Adenylate cyclase",
233,Eosinophil chemotaxis in asthma,64,1.707E-01,7.046E-01,1.839E-01,7.046E-01,3,"IL8RA, PI3K reg class IB (p101), CCR8",1.707E-01,8.219E-01,3,"IL8RA, PI3K reg class IB (p101), CCR8",
234,Development_FGF2 signaling during embryonic stem cell differentiation,34,1.748E-01,7.046E-01,1.850E-01,7.046E-01,2,"SOX2, SOX3",1.748E-01,8.219E-01,2,"SOX2, SOX3",
235,Nicotine / Beta-adrenergic signaling in lung cancer,34,1.748E-01,7.046E-01,1.850E-01,7.046E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",1.748E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
236,G-protein signaling_RhoA regulation pathway,34,1.748E-01,7.046E-01,1.850E-01,7.046E-01,2,"Ephrin-A receptors, Rhophilin 1",1.748E-01,8.219E-01,2,"Ephrin-A receptors, Rhophilin 1",
237,Th2 cell migration in asthma,34,1.748E-01,7.046E-01,1.850E-01,7.046E-01,2,"PI3K reg class IB (p101), CCR8",1.748E-01,8.219E-01,2,"PI3K reg class IB (p101), CCR8",
238,Development_Role of CDK5 in neuronal development,34,1.748E-01,7.046E-01,1.850E-01,7.046E-01,2,"Delta-catenin, Tau (MAPT)",1.748E-01,8.219E-01,2,"Delta-catenin, Tau (MAPT)",
239,p53 signaling in Prostate Cancer,33,1.766E-01,7.008E-01,1.766E-01,7.008E-01,2,"Androgen receptor, PTEN",5.250E-01,8.219E-01,1,Androgen receptor,
240,SDF-1 axis in endothelial progenitor cell recruitment in healing myocardial infarction,33,1.766E-01,7.008E-01,1.766E-01,7.008E-01,2,"Tuberin, PI3K reg class IB (p101)",5.250E-01,8.219E-01,1,PI3K reg class IB (p101),
241,Development_TGF-beta-dependent induction of EMT via SMADs ,35,1.829E-01,7.194E-01,1.934E-01,7.194E-01,2,"TGF-beta 3, TGF-beta",1.829E-01,8.219E-01,2,"TGF-beta 3, TGF-beta",
242,Development_Schema: Adult neuron differentiation in the Subventricular and Subgranular Zones,35,1.829E-01,7.194E-01,1.934E-01,7.194E-01,2,"TY3H, SOX2",1.829E-01,8.219E-01,2,"TY3H, SOX2",
243,Beta-alanine metabolism,35,1.829E-01,7.194E-01,1.934E-01,7.194E-01,2,"GABT, ABP1",1.829E-01,8.219E-01,2,"GABT, ABP1",
244,Apoptosis and survival_Role of CDK5 in neuronal death and survival,34,1.850E-01,7.046E-01,1.850E-01,7.046E-01,2,"Bcl-2, ErbB3",5.356E-01,8.219E-01,1,Bcl-2,
245,Development_Histone acetylation in embryonic stem cells,34,1.850E-01,7.046E-01,1.850E-01,7.046E-01,2,"SOX2, p27KIP1",5.356E-01,8.219E-01,1,SOX2,
246,Inflammatory mechanisms of pancreatic cancerogenesis,67,1.874E-01,7.309E-01,2.016E-01,7.309E-01,3,"C/EBP, IL8RA, Bcl-2",1.874E-01,8.219E-01,3,"C/EBP, IL8RA, Bcl-2",
247,Development_Role of IL-8 in angiogenesis,65,1.898E-01,7.194E-01,1.898E-01,7.194E-01,3,"IL8RA, FASN, PI3K reg class IB (p101)",4.267E-01,8.219E-01,2,"IL8RA, PI3K reg class IB (p101)",
248,Development_EPO-induced Jak-STAT pathway,36,1.909E-01,7.309E-01,2.018E-01,7.309E-01,2,"CISH, Bcl-2",1.909E-01,8.219E-01,2,"CISH, Bcl-2",
249,Beta-catenin-dependent transcription regulation in colorectal cancer,36,1.909E-01,7.309E-01,2.018E-01,7.309E-01,2,"Mucin 2, NRCAM",1.909E-01,8.219E-01,2,"Mucin 2, NRCAM",
250,Nitrogen metabolism,36,1.909E-01,7.309E-01,2.018E-01,7.309E-01,2,"DHE4, Carbonic anhydrase XII",1.909E-01,8.219E-01,2,"DHE4, Carbonic anhydrase XII",
251,Autophagy_Autophagy,35,1.934E-01,7.194E-01,1.934E-01,7.194E-01,2,"Bcl-2, Beclin 1",5.459E-01,8.219E-01,1,Bcl-2,
252,Cell cycle_ESR1 regulation of G1/S transition,35,1.934E-01,7.194E-01,1.934E-01,7.194E-01,2,"ESR1 (nuclear), p27KIP1",5.459E-01,8.219E-01,1,ESR1 (nuclear),
253,IL-6 signaling in colorectal cancer,37,1.991E-01,7.447E-01,2.103E-01,7.447E-01,2,"TFF3, Clusterin",1.991E-01,8.219E-01,2,"TFF3, Clusterin",
254,Immune response_IL-7 signaling in T lymphocytes,37,1.991E-01,7.447E-01,2.103E-01,7.447E-01,2,"TCR gamma locus, Bcl-2",1.991E-01,8.219E-01,2,"TCR gamma locus, Bcl-2",
255,Cholehepatic circulation of bile acids / Rodent version,37,1.991E-01,7.447E-01,2.103E-01,7.447E-01,2,"ABCC11, OATP-A",1.991E-01,8.219E-01,2,"ABCC11, OATP-A",
256,Apoptosis and survival_Anti-apoptotic action of nuclear ESR1 and ESR2,37,1.991E-01,7.447E-01,2.103E-01,7.447E-01,2,"ESR1 (nuclear), Bcl-2",1.991E-01,8.219E-01,2,"ESR1 (nuclear), Bcl-2",
257,Development_Early embryonal hypaxial myogenesis,37,1.991E-01,7.447E-01,2.103E-01,7.447E-01,2,"FGFR4, Adenylate cyclase",1.991E-01,8.219E-01,2,"FGFR4, Adenylate cyclase",
258,Role of neuropeptides in pathogenesis of SCLC,67,2.016E-01,7.309E-01,2.016E-01,7.309E-01,3,"GRP-R, BDKRB2, ErbB3",4.419E-01,8.219E-01,2,"GRP-R, BDKRB2",
259,Development_Beta adrenergic receptors in brown adipocyte differentiation,36,2.018E-01,7.309E-01,2.018E-01,7.309E-01,2,"FASN, Adenylate cyclase",5.561E-01,8.219E-01,1,Adenylate cyclase,
260,Upregulation of MITF in melanoma,36,2.018E-01,7.309E-01,2.018E-01,7.309E-01,2,"p27KIP1, Bcl-2",5.561E-01,8.219E-01,1,Bcl-2,
261,Retinol metabolism,70,2.045E-01,7.485E-01,2.196E-01,7.485E-01,3,"CYP2A6, CYP2B6, CRABP1",2.045E-01,8.219E-01,3,"CYP2A6, CYP2B6, CRABP1",
262,Neutrophil chemotaxis in asthma,38,2.072E-01,7.485E-01,2.188E-01,7.485E-01,2,"IL8RA, PI3K reg class IB (p101)",2.072E-01,8.219E-01,2,"IL8RA, PI3K reg class IB (p101)",
263,Apoptosis and survival_Anti-apoptotic action of membrane-bound ESR1,38,2.072E-01,7.485E-01,2.188E-01,7.485E-01,2,"ESR1 (membrane), Bcl-2",2.072E-01,8.219E-01,2,"ESR1 (membrane), Bcl-2",
264,WNT signaling in proliferative-type melanoma cells,38,2.072E-01,7.485E-01,2.188E-01,7.485E-01,2,"MSG1, NRCAM",2.072E-01,8.219E-01,2,"MSG1, NRCAM",
265,Cell adhesion_Tight junctions,38,2.072E-01,7.485E-01,2.188E-01,7.485E-01,2,"Claudin-3, WNK4",2.072E-01,8.219E-01,2,"Claudin-3, WNK4",
266,Cell adhesion_Cell-matrix glycoconjugates,38,2.072E-01,7.485E-01,2.188E-01,7.485E-01,2,"CEACAM5, A1M",2.072E-01,8.219E-01,2,"CEACAM5, A1M",
267,Blood coagulation_GPCRs in platelet aggregation,71,2.103E-01,7.485E-01,2.257E-01,7.485E-01,3,"PI3K reg class IB (p101), Adenylate cyclase, Alpha-2A adrenergic receptor",2.103E-01,8.219E-01,3,"PI3K reg class IB (p101), Adenylate cyclase, Alpha-2A adrenergic receptor",
268,Development_Growth factors in regulation of oligodendrocyte precursor cell survival,37,2.103E-01,7.447E-01,2.103E-01,7.447E-01,2,"Bcl-2, ErbB3",5.660E-01,8.219E-01,1,Bcl-2,
269,Transcription_Negative regulation of HIF1A function,69,2.136E-01,7.485E-01,2.136E-01,7.485E-01,3,"PTEN, MTG16 (CBFA2T3), KLF2",4.569E-01,8.219E-01,2,"MTG16 (CBFA2T3), KLF2",
270,"Immune response_Th17, Th22 and Th9 cell differentiation ",39,2.154E-01,7.485E-01,2.274E-01,7.485E-01,2,"GATA-3, ROR-gamma",2.154E-01,8.219E-01,2,"GATA-3, ROR-gamma",
271,Immune response_TSLP signalling,39,2.154E-01,7.485E-01,2.274E-01,7.485E-01,2,"CISH, Bcl-2",2.154E-01,8.219E-01,2,"CISH, Bcl-2",
272,Development_PACAP signaling in neural cells,39,2.154E-01,7.485E-01,2.274E-01,7.485E-01,2,"TY3H, Bcl-2",2.154E-01,8.219E-01,2,"TY3H, Bcl-2",
273,Blood coagulation_Blood coagulation,39,2.154E-01,7.485E-01,2.274E-01,7.485E-01,2,"Alpha 1-antitrypsin, Coagulation factor VII",2.154E-01,8.219E-01,2,"Alpha 1-antitrypsin, Coagulation factor VII",
274,ATP metabolism,107,2.157E-01,7.485E-01,2.346E-01,7.485E-01,4,"ENPP1, Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",2.157E-01,8.219E-01,4,"ENPP1, Adenylate cyclase type IV, Adenylate cyclase type V, Adenylate cyclase type II",
275,Development_Mu-type opioid receptor signaling,38,2.188E-01,7.485E-01,2.188E-01,7.485E-01,2,"Tuberin, PI3K reg class IB (p101)",5.757E-01,8.219E-01,1,PI3K reg class IB (p101),
276,Cell cycle_Regulation of G1/S transition (part 1),38,2.188E-01,7.485E-01,2.188E-01,7.485E-01,2,"PP2A regulatory, p27KIP1",5.757E-01,8.219E-01,1,PP2A regulatory,
277,Reproduction_Gonadotropin-releasing hormone (GnRH) signaling,73,2.219E-01,7.485E-01,2.380E-01,7.485E-01,3,"MKP-2, CG alpha, Adenylate cyclase",2.219E-01,8.219E-01,3,"MKP-2, CG alpha, Adenylate cyclase",
278,Mast cell migration in asthma,73,2.219E-01,7.485E-01,2.380E-01,7.485E-01,3,"IL8RA, TGF-beta 3, PI3K reg class IB (p101)",2.219E-01,8.219E-01,3,"IL8RA, TGF-beta 3, PI3K reg class IB (p101)",
279,Neurophysiological process_Delta-type opioid receptor in the nervous system,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"Adenylate cyclase type II, PDE1B",2.237E-01,8.219E-01,2,"Adenylate cyclase type II, PDE1B",
280,Activation of Cortisol production in major depressive disorder,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"Adenylate cyclase type V, CYP11B2",2.237E-01,8.219E-01,2,"Adenylate cyclase type V, CYP11B2",
281,CAR-mediated direct regulation of xenobiotic metabolizing enzymes / Human version,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"CYP2A6, CYP2B6",2.237E-01,8.219E-01,2,"CYP2A6, CYP2B6",
282,Development_WNT/Beta-catenin and NOTCH in induction of osteogenesis,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"Adiponectin, C/EBPalpha",2.237E-01,8.219E-01,2,"Adiponectin, C/EBPalpha",
283,Recurrent gene fusions in Prostate Cancer,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"Androgen receptor, ERG",2.237E-01,8.219E-01,2,"Androgen receptor, ERG",
284,Neurophysiological process_ACM1 and ACM2 in neuronal membrane polarization,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"Kir3.1, Kir2.2",2.237E-01,8.219E-01,2,"Kir3.1, Kir2.2",
285,Development_FGF signaling in pancreatic and hepatic differentiation of embryonic stem cells,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"Alpha 1-antitrypsin, FGFR4",2.237E-01,8.219E-01,2,"Alpha 1-antitrypsin, FGFR4",
286,Enterohepatic circulation of bile acids / Rodent version,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"ABCC11, OATP-A",2.237E-01,8.219E-01,2,"ABCC11, OATP-A",
287,Androstenedione and testosterone biosynthesis and metabolism p.3,40,2.237E-01,7.485E-01,2.360E-01,7.485E-01,2,"UGT2B28, UGT2B17",2.237E-01,8.219E-01,2,"UGT2B28, UGT2B17",
288,Development_Stimulation of differentiation of mouse embryonic fibroblasts into adipocytes by extracellular factors,71,2.257E-01,7.485E-01,2.257E-01,7.485E-01,3,"Tuberin, Adenylate cyclase, C/EBPalpha",4.717E-01,8.219E-01,2,"Adenylate cyclase, C/EBPalpha",
289,Immune response_IL-6 signaling pathway via JAK/STAT,71,2.257E-01,7.485E-01,2.257E-01,7.485E-01,3,"p27KIP1, ROR-gamma, CISH",4.717E-01,8.219E-01,2,"ROR-gamma, CISH",
290,Development_ERBB-family signaling,39,2.274E-01,7.485E-01,2.274E-01,7.485E-01,2,"Neuregulin 3, ErbB3",5.852E-01,8.219E-01,1,Neuregulin 3,
291,FGF2 signaling in melanoma,39,2.274E-01,7.485E-01,2.274E-01,7.485E-01,2,"FGFR4, N-Ras",5.852E-01,8.219E-01,1,FGFR4,
292,L-Phenylalanine metabolism,74,2.278E-01,7.567E-01,2.442E-01,7.567E-01,3,"SLC7A8, GLYATL1, PAH",2.278E-01,8.219E-01,3,"SLC7A8, GLYATL1, PAH",
293,Role of epigenetic alterations in proliferation and differentiation of SCLC cells,72,2.319E-01,7.485E-01,2.319E-01,7.485E-01,3,"p27KIP1, LIN-28, C/EBPalpha",4.790E-01,8.219E-01,2,"LIN-28, C/EBPalpha",
294,Regulation of beta-adrenergic receptors signaling in pancreatic cancer,41,2.319E-01,7.567E-01,2.446E-01,7.567E-01,2,"Adenylate cyclase, nAChR alpha-4",2.319E-01,8.219E-01,2,"Adenylate cyclase, nAChR alpha-4",
295,Translation_(L)-selenoaminoacids incorporation in proteins during translation,41,2.319E-01,7.567E-01,2.446E-01,7.567E-01,2,"Selenoprotein P, DIO1",2.319E-01,8.219E-01,2,"Selenoprotein P, DIO1",
296,Catecholamine metabolism,75,2.337E-01,7.635E-01,2.504E-01,7.635E-01,3,"SULT1A1, TY3H, PNMT",2.337E-01,8.219E-01,3,"SULT1A1, TY3H, PNMT",
297,Transport_ACM3 signaling in lacrimal glands,75,2.337E-01,7.635E-01,2.504E-01,7.635E-01,3,"Mucin 5B, MaxiK alpha subunit, SP-D",2.337E-01,8.219E-01,3,"Mucin 5B, MaxiK alpha subunit, SP-D",
298,Development_Role of Activin A in cell differentiation and proliferation,40,2.360E-01,7.485E-01,2.360E-01,7.485E-01,2,"p27KIP1, Adenylate cyclase",5.944E-01,8.219E-01,1,Adenylate cyclase,
299,CHDI_Correlations from Discovery data_Causal network,73,2.380E-01,7.485E-01,2.380E-01,7.485E-01,3,"PTEN, Tuberin, PI3K reg class IB (p101)",8.078E-01,8.438E-01,1,PI3K reg class IB (p101),
300,Stromal-epithelial interaction in Prostate Cancer,42,2.402E-01,7.635E-01,2.532E-01,7.635E-01,2,"Androgen receptor, TGF-beta 3",2.402E-01,8.219E-01,2,"Androgen receptor, TGF-beta 3",
301,CFTR-dependent regulation of ion channels in CF,42,2.402E-01,7.635E-01,2.532E-01,7.635E-01,2,"EBP50, CLCA2",2.402E-01,8.219E-01,2,"EBP50, CLCA2",
302,Transcription targets of Androgen receptor involved in Prostate Cancer,42,2.402E-01,7.635E-01,2.532E-01,7.635E-01,2,"Androgen receptor, Clusterin",2.402E-01,8.219E-01,2,"Androgen receptor, Clusterin",
303,Development_TGF-beta family mediated differentiation of embryonic stem cells,42,2.402E-01,7.635E-01,2.532E-01,7.635E-01,2,"SOX2, SOX3",2.402E-01,8.219E-01,2,"SOX2, SOX3",
304,Cell adhesion_Integrin inside-out signaling in neutrophils,77,2.456E-01,7.638E-01,2.629E-01,7.638E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",2.456E-01,8.219E-01,3,"IL8RA, PI3K reg class IB (p101), PREX1",
305,Apoptosis and survival_NGF/ TrkA PI3K-mediated signaling,77,2.456E-01,7.638E-01,2.629E-01,7.638E-01,3,"Tau (MAPT), Bcl-2, PREX1",2.456E-01,8.219E-01,3,"Tau (MAPT), Bcl-2, PREX1",
306,ESR1 (membrane) 36 kDa isoform signaling in breast cancer,43,2.485E-01,7.638E-01,2.618E-01,7.638E-01,2,"ESR1 (membrane), Gamma-synuclein",2.485E-01,8.219E-01,2,"ESR1 (membrane), Gamma-synuclein",
307,Regulation of proinflammatory cytokine production by Th2 cells in asthma,43,2.485E-01,7.638E-01,2.618E-01,7.638E-01,2,"IL-19, GATA-3",2.485E-01,8.219E-01,2,"IL-19, GATA-3",
308,Development_S1P3 receptor signaling pathway,43,2.485E-01,7.638E-01,2.618E-01,7.638E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",2.485E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
309,Development_WNT/Beta-catenin signaling in embryogenesis,43,2.485E-01,7.638E-01,2.618E-01,7.638E-01,2,"LHX8, SOX2",2.485E-01,8.219E-01,2,"LHX8, SOX2",
310,Role of epigenetic alterations in survival and migration of SCLC cells,43,2.485E-01,7.638E-01,2.618E-01,7.638E-01,2,"H-cadherin, Bcl-2",2.485E-01,8.219E-01,2,"H-cadherin, Bcl-2",
311,Role of platelets in allograft rejection,43,2.485E-01,7.638E-01,2.618E-01,7.638E-01,2,"TGF-beta, Kainate receptor",2.485E-01,8.219E-01,2,"TGF-beta, Kainate receptor",
312,Apoptosis and survival_BAD phosphorylation,42,2.532E-01,7.635E-01,2.532E-01,7.635E-01,2,"Bcl-2, Beclin 1",6.124E-01,8.219E-01,1,Bcl-2,
313,Development_Growth hormone signaling via PI3K/AKT and MAPK cascades,42,2.532E-01,7.635E-01,2.532E-01,7.635E-01,2,"Tuberin, GHR",6.124E-01,8.219E-01,1,GHR,
314,Development_Role of nicotinamide in G-CSF-induced granulopoiesis,13,2.540E-01,7.638E-01,2.622E-01,7.638E-01,1,C/EBPalpha,2.540E-01,8.219E-01,1,C/EBPalpha,
315,SHH signaling in oligodendrocyte precursor cells differentiation in multiple sclerosis,13,2.540E-01,7.638E-01,2.622E-01,7.638E-01,1,Nkx2.2,2.540E-01,8.219E-01,1,Nkx2.2,
316,Immune response_IL-13 signaling via JAK-STAT,44,2.568E-01,7.717E-01,2.704E-01,7.717E-01,2,"IGHG4, IGHE",2.568E-01,8.219E-01,2,"IGHG4, IGHE",
317,Immune response_CRTH2 signaling in Th2 cells,44,2.568E-01,7.717E-01,2.704E-01,7.717E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",2.568E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
318,Release of pro-inflammatory factors and proteases by alveolar macrophages in asthma,44,2.568E-01,7.717E-01,2.704E-01,7.717E-01,2,"SP-D, IL-30",2.568E-01,8.219E-01,2,"SP-D, IL-30",
319,Apoptosis and survival_Inhibition of ROS-induced apoptosis by 17beta-estradiol,44,2.568E-01,7.717E-01,2.704E-01,7.717E-01,2,"ESR1 (mitochondrial), Bcl-2",2.568E-01,8.219E-01,2,"ESR1 (mitochondrial), Bcl-2",
320,Inhibition of remyelination in multiple sclerosis: regulation of cytoskeleton proteins,44,2.568E-01,7.717E-01,2.704E-01,7.717E-01,2,"TGF-beta, Tau (MAPT)",2.568E-01,8.219E-01,2,"TGF-beta, Tau (MAPT)",
321,Regulation of metabolism_Role of Adiponectin in regulation of metabolism,43,2.618E-01,7.638E-01,2.618E-01,7.638E-01,2,"Adiponectin, Tuberin",6.210E-01,8.219E-01,1,Adiponectin,
322,Regulation of Tissue factor signaling in cancer,43,2.618E-01,7.638E-01,2.618E-01,7.638E-01,2,"PTEN, Coagulation factor VII",6.210E-01,8.219E-01,1,Coagulation factor VII,
323,Nicotine signaling in chromaffin cells,45,2.651E-01,7.738E-01,2.790E-01,7.738E-01,2,"Chapsyn-110, TY3H",2.651E-01,8.219E-01,2,"Chapsyn-110, TY3H",
324,Neurophysiological process_Glutamic acid regulation of Dopamine D1A receptor signaling,45,2.651E-01,7.738E-01,2.790E-01,7.738E-01,2,"PP2A regulatory, Adenylate cyclase type V",2.651E-01,8.219E-01,2,"PP2A regulatory, Adenylate cyclase type V",
325,Immune response_PGE2 signaling in immune response,45,2.651E-01,7.738E-01,2.790E-01,7.738E-01,2,"Adenylate cyclase, CCR5",2.651E-01,8.219E-01,2,"Adenylate cyclase, CCR5",
326,Role of DNA methylation in progression of multiple myeloma,45,2.651E-01,7.738E-01,2.790E-01,7.738E-01,2,"ESR1 (nuclear), Dexras1",2.651E-01,8.219E-01,2,"ESR1 (nuclear), Dexras1",
327,Role of mevalonate pathway in multiple myeloma,44,2.704E-01,7.717E-01,2.704E-01,7.717E-01,2,"RhoB, N-Ras",6.295E-01,8.219E-01,1,RhoB,
328,Riboflavin metabolism,14,2.706E-01,7.738E-01,2.792E-01,7.738E-01,1,ENPP1,2.706E-01,8.219E-01,1,ENPP1,
329,Type 2 diabetes (general schema),14,2.706E-01,7.738E-01,2.792E-01,7.738E-01,1,Adiponectin,2.706E-01,8.219E-01,1,Adiponectin,
330,Asthma-specific pathways of airway smooth muscle cell proliferation,14,2.706E-01,7.738E-01,2.792E-01,7.738E-01,1,C/EBPalpha,2.706E-01,8.219E-01,1,C/EBPalpha,
331,Immune response_Naive CD4+ T cell differentiation,46,2.734E-01,7.801E-01,2.876E-01,7.801E-01,2,"GATA-3, ROR-gamma",2.734E-01,8.219E-01,2,"GATA-3, ROR-gamma",
332,Signal transduction_CXCR4 signaling via PI3K cascade,46,2.734E-01,7.801E-01,2.876E-01,7.801E-01,2,"PI3K reg class IB (p101), PREX1",2.734E-01,8.219E-01,2,"PI3K reg class IB (p101), PREX1",
333,Nociception_Expression and role of Nociceptin in immune system,46,2.734E-01,7.801E-01,2.876E-01,7.801E-01,2,"ESR1 (nuclear), CaMK II beta",2.734E-01,8.219E-01,2,"ESR1 (nuclear), CaMK II beta",
334,L-Alanine and L-cysteine metabolism,46,2.734E-01,7.801E-01,2.876E-01,7.801E-01,2,"AGT2, AGXT",2.734E-01,8.219E-01,2,"AGT2, AGXT",
335,Cytoskeleton remodeling_Regulation of actin cytoskeleton nucleation and polymerization by Rho GTPases,46,2.734E-01,7.801E-01,2.876E-01,7.801E-01,2,"RhoA-related, RhoB",2.734E-01,8.219E-01,2,"RhoA-related, RhoB",
336,SCAP/SREBP Transcriptional Control of Cholesterol and FA Biosynthesis,45,2.790E-01,7.738E-01,2.790E-01,7.738E-01,2,"FASN, HMGCS2",6.378E-01,8.219E-01,1,HMGCS2,
337,Immune response_PGE2 in immune and neuroendocrine system interactions,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"PGE2R3, PLA2(hGIIA)",2.817E-01,8.219E-01,2,"PGE2R3, PLA2(hGIIA)",
338,Chemotaxis_Lipoxin inhibitory action on Formyl-Met-Leu-Phe-induced neutrophil chemotaxis,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"PI3K reg class IB (p101), PREX1",2.817E-01,8.219E-01,2,"PI3K reg class IB (p101), PREX1",
339,Immune response_PGE2 common pathways,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"PGE2R3, Adenylate cyclase",2.817E-01,8.219E-01,2,"PGE2R3, Adenylate cyclase",
340,Transport_Alpha-2 adrenergic receptor regulation of ion channels,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"Adenylate cyclase type V, Alpha-2A adrenergic receptor",2.817E-01,8.219E-01,2,"Adenylate cyclase type V, Alpha-2A adrenergic receptor",
341,Development_Beta-adrenergic receptor-induced regulation of ERK,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",2.817E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
342,Th9 cells in asthma,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"GATA-3, TGF-beta",2.817E-01,8.219E-01,2,"GATA-3, TGF-beta",
343,Neurophysiological process_PGE2-induced pain processing,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"PGE2R3, Adenylate cyclase",2.817E-01,8.219E-01,2,"PGE2R3, Adenylate cyclase",
344,Role of proinflammatory cytokines in activation of p53 in major depressive disorder,47,2.817E-01,7.801E-01,2.962E-01,7.801E-01,2,"TGF-beta, Bcl-2",2.817E-01,8.219E-01,2,"TGF-beta, Bcl-2",
345,Tyrosine metabolism p.2 (melanin),83,2.818E-01,7.857E-01,3.007E-01,7.857E-01,3,"PERT, TAT, ABP1",2.818E-01,8.219E-01,3,"PERT, TAT, ABP1",
346,Development_Ligand-dependent activation of the ESR1/AP-1 pathway,15,2.869E-01,7.801E-01,2.959E-01,7.801E-01,1,ESR1 (nuclear),2.869E-01,8.219E-01,1,ESR1 (nuclear),
347,Metabolic syndrome X (general schema),15,2.869E-01,7.801E-01,2.959E-01,7.801E-01,1,Adiponectin,2.869E-01,8.219E-01,1,Adiponectin,
348,"Chemokines in inflammation in adipose tissue and liver in obesity, type 2 diabetes and metabolic syndrome X",48,2.900E-01,7.857E-01,3.048E-01,7.857E-01,2,"CX3CR1, CCR5",2.900E-01,8.219E-01,2,"CX3CR1, CCR5",
349,Immune response_C3a signaling,48,2.900E-01,7.857E-01,3.048E-01,7.857E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",2.900E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
350,Neurophysiological process_ACM regulation of nerve impulse,48,2.900E-01,7.857E-01,3.048E-01,7.857E-01,2,"CACNA1I, CACNA1H",2.900E-01,8.219E-01,2,"CACNA1I, CACNA1H",
351,Stimulation of TGF-beta signaling in lung cancer,48,2.900E-01,7.857E-01,3.048E-01,7.857E-01,2,"TGF-beta 3, TGF-beta",2.900E-01,8.219E-01,2,"TGF-beta 3, TGF-beta",
352,Immune response_Antigen presentation by MHC class II,118,2.907E-01,7.801E-01,2.907E-01,7.801E-01,4,"MHC class II alpha chain, RhoB, Bcl-2, Beclin 1",4.912E-01,8.219E-01,3,"MHC class II alpha chain, RhoB, Bcl-2",
353,Canonical Notch signaling pathway in colorectal cancer,47,2.962E-01,7.801E-01,2.962E-01,7.801E-01,2,"Mucin 2, p27KIP1",6.538E-01,8.219E-01,1,Mucin 2,
354,Mechanisms of drug resistance in multiple myeloma,49,2.982E-01,7.857E-01,3.134E-01,7.857E-01,2,"IL8RA, Bcl-2",2.982E-01,8.219E-01,2,"IL8RA, Bcl-2",
355,Neurophysiological process_HTR2A signaling in the nervous system,49,2.982E-01,7.857E-01,3.134E-01,7.857E-01,2,"GABA-A receptor gamma-2 subunit, SFK",2.982E-01,8.219E-01,2,"GABA-A receptor gamma-2 subunit, SFK",
356,Neutrophil-derived granule proteins and cytokines in asthma,49,2.982E-01,7.857E-01,3.134E-01,7.857E-01,2,"Tryptase, IL8RA",2.982E-01,8.219E-01,2,"Tryptase, IL8RA",
357,G-protein signaling_RhoB regulation pathway,16,3.028E-01,7.857E-01,3.122E-01,7.857E-01,1,RhoB,3.028E-01,8.219E-01,1,RhoB,
358,"Mechanism of Pioglitazone/ Metformin and Rosiglitazone/ Metformin  cooperative action in Diabetes mellitus, Type 2",16,3.028E-01,7.857E-01,3.122E-01,7.857E-01,1,Adiponectin,3.028E-01,8.219E-01,1,Adiponectin,
359,c-Myc in multiple myeloma,16,3.028E-01,7.857E-01,3.122E-01,7.857E-01,1,C/EBPalpha,3.028E-01,8.219E-01,1,C/EBPalpha,
360,Development_Adiponectin signaling,48,3.048E-01,7.857E-01,3.048E-01,7.857E-01,2,"Adiponectin, A-Raf-1",6.615E-01,8.219E-01,1,Adiponectin,
361,Development_Role of Thyroid hormone in regulation of oligodendrocyte differentiation,48,3.048E-01,7.857E-01,3.048E-01,7.857E-01,2,"p27KIP1, OATP-A",6.615E-01,8.219E-01,1,OATP-A,
362,Rheumatoid arthritis (general schema),50,3.065E-01,7.857E-01,3.219E-01,7.857E-01,2,"TGF-beta, Collagen II",3.065E-01,8.219E-01,2,"TGF-beta, Collagen II",
363,TGF-beta signaling via microRNA in breast cancer,50,3.065E-01,7.857E-01,3.219E-01,7.857E-01,2,"TGF-beta 3, Bcl-2",3.065E-01,8.219E-01,2,"TGF-beta 3, Bcl-2",
364,Immune response_IFN-gamma in macrophages activation,50,3.065E-01,7.857E-01,3.219E-01,7.857E-01,2,"Selenoprotein P, IL-30",3.065E-01,8.219E-01,2,"Selenoprotein P, IL-30",
365,Development_GM-CSF signaling,50,3.065E-01,7.857E-01,3.219E-01,7.857E-01,2,"CISH, Bcl-2",3.065E-01,8.219E-01,2,"CISH, Bcl-2",
366,Immune response_C5a signaling,50,3.065E-01,7.857E-01,3.219E-01,7.857E-01,2,"Bcl-2, PREX1",3.065E-01,8.219E-01,2,"Bcl-2, PREX1",
367,Protein folding and maturation_Posttranslational processing of neuroendocrine peptides,50,3.065E-01,7.857E-01,3.219E-01,7.857E-01,2,"PC2, Carboxypeptidase H",3.065E-01,8.219E-01,2,"PC2, Carboxypeptidase H",
368,Immune response_IL-13 signaling via PI3K-ERK pathway,50,3.065E-01,7.857E-01,3.219E-01,7.857E-01,2,"Mucin 5AC, IGHE",3.065E-01,8.219E-01,2,"Mucin 5AC, IGHE",
369,Development_Beta-adrenergic receptors signaling via Cyclic AMP,51,3.148E-01,7.857E-01,3.304E-01,7.857E-01,2,"Adenylate cyclase, Perilipin",3.148E-01,8.219E-01,2,"Adenylate cyclase, Perilipin",
370,Immune response_Histamine signaling in dendritic cells,51,3.148E-01,7.857E-01,3.304E-01,7.857E-01,2,"Histamine H3 receptor, Adenylate cyclase",3.148E-01,8.219E-01,2,"Histamine H3 receptor, Adenylate cyclase",
371,"Development_Hedgehog, BMP and Parathyroid hormone in osteogenesis",51,3.148E-01,7.857E-01,3.304E-01,7.857E-01,2,"PTHR1, Adenylate cyclase",3.148E-01,8.219E-01,2,"PTHR1, Adenylate cyclase",
372,LRRK2 in neuronal apoptosis in Parkinson's disease,17,3.183E-01,7.857E-01,3.281E-01,7.857E-01,1,LRRK2,3.183E-01,8.219E-01,1,LRRK2,
373,G-protein signaling_Rac3 regulation pathway,17,3.183E-01,7.857E-01,3.281E-01,7.857E-01,1,Androgen receptor,3.183E-01,8.219E-01,1,Androgen receptor,
374,Development_FGF10 in development of subcutaneous white adipose tissue in embryogenesis,17,3.183E-01,7.857E-01,3.281E-01,7.857E-01,1,C/EBPalpha,3.183E-01,8.219E-01,1,C/EBPalpha,
375,Putative mechanism of drug action for CCR5 antagonists,17,3.183E-01,7.857E-01,3.281E-01,7.857E-01,1,CCR5,3.183E-01,8.219E-01,1,CCR5,
376,DeltaF508-CFTR traffic / ER-to-Golgi in CF,17,3.183E-01,7.857E-01,3.281E-01,7.857E-01,1,EBP50,3.183E-01,8.219E-01,1,EBP50,
377,Involvement of VEGF signaling in the progression of lung cancer,17,3.183E-01,7.857E-01,3.281E-01,7.857E-01,1,C/EBPalpha,3.183E-01,8.219E-01,1,C/EBPalpha,
378,wtCFTR traffic / ER-to-Golgi (normal),17,3.183E-01,7.857E-01,3.281E-01,7.857E-01,1,EBP50,3.183E-01,8.219E-01,1,EBP50,
379,"Cigarette smoke-induced proliferation, metaplasia and survival of airway epithelial cells ",50,3.219E-01,7.857E-01,3.219E-01,7.857E-01,2,"nAChR alpha-4, ErbB3",6.765E-01,8.219E-01,1,nAChR alpha-4,
380,Modulation of tumor response to cytotoxic T cells by hypoxia in tumors,50,3.219E-01,7.857E-01,3.219E-01,7.857E-01,2,"Bcl-2, Beclin 1",6.765E-01,8.219E-01,1,Bcl-2,
381,TGF-beta 1-induced transactivation of membrane receptors signaling in HCC,50,3.219E-01,7.857E-01,3.219E-01,7.857E-01,2,"PTEN, TGF-beta",6.765E-01,8.219E-01,1,TGF-beta,
382,Nicotine signaling in cholinergic neurons,52,3.230E-01,7.887E-01,3.389E-01,7.887E-01,2,"Tau (MAPT), nAChR alpha-4",3.230E-01,8.219E-01,2,"Tau (MAPT), nAChR alpha-4",
383,Signal transduction_Additional pathways of NF-kB activation (in the cytoplasm),52,3.230E-01,7.887E-01,3.389E-01,7.887E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",3.230E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
384,G-protein signaling_Proinsulin C-peptide signaling,52,3.230E-01,7.887E-01,3.389E-01,7.887E-01,2,"PI3K reg class IB (p101), Bcl-2",3.230E-01,8.219E-01,2,"PI3K reg class IB (p101), Bcl-2",
385,Immune response_T cell subsets: cell surface markers,52,3.230E-01,7.887E-01,3.389E-01,7.887E-01,2,"CCR8, CCR5",3.230E-01,8.219E-01,2,"CCR8, CCR5",
386,Some pathways of EMT in cancer cells,51,3.304E-01,7.857E-01,3.304E-01,7.857E-01,2,"Tuberin, Bcl-2",6.838E-01,8.219E-01,1,Bcl-2,
387,Role of tumor-infiltrating B cells in anti-tumor immunity,91,3.307E-01,7.905E-01,3.515E-01,7.905E-01,3,"SOX2, MAGE-1 antigen, NY-ESO-1",3.307E-01,8.219E-01,3,"SOX2, MAGE-1 antigen, NY-ESO-1",
388,Chemotaxis_CCR1 signaling,53,3.312E-01,7.887E-01,3.473E-01,7.887E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",3.312E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
389,IL-6 signaling in breast cancer cells,53,3.312E-01,7.887E-01,3.473E-01,7.887E-01,2,"ESR1 (nuclear), Bcl-2",3.312E-01,8.219E-01,2,"ESR1 (nuclear), Bcl-2",
390,Notch signaling in breast cancer,53,3.312E-01,7.887E-01,3.473E-01,7.887E-01,2,"ESR1 (nuclear), TFF1",3.312E-01,8.219E-01,2,"ESR1 (nuclear), TFF1",
391,Proinflammatory cytokine production by Th17 cells in asthma,53,3.312E-01,7.887E-01,3.473E-01,7.887E-01,2,"GATA-3, ROR-gamma",3.312E-01,8.219E-01,2,"GATA-3, ROR-gamma",
392,Beta-adrenergic-dependent CFTR expression,18,3.335E-01,7.887E-01,3.437E-01,7.887E-01,1,Adenylate cyclase,3.335E-01,8.219E-01,1,Adenylate cyclase,
393,Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 1 activity,18,3.335E-01,7.887E-01,3.437E-01,7.887E-01,1,ACACB,3.335E-01,8.219E-01,1,ACACB,
394,Androgen signaling in HCC,18,3.335E-01,7.887E-01,3.437E-01,7.887E-01,1,Androgen receptor,3.335E-01,8.219E-01,1,Androgen receptor,
395,FGF2 in multiple myeloma,18,3.335E-01,7.887E-01,3.437E-01,7.887E-01,1,FGFR4,3.335E-01,8.219E-01,1,FGFR4,
396,Stem cells_CD30 signaling in transformed embryonic stem cells,18,3.335E-01,7.887E-01,3.437E-01,7.887E-01,1,SOX2,3.335E-01,8.219E-01,1,SOX2,
397,Glomerular injury in Lupus Nephritis,92,3.368E-01,7.905E-01,3.578E-01,7.905E-01,3,"TGF-beta, LIN-28, Bcl-2",3.368E-01,8.219E-01,3,"TGF-beta, LIN-28, Bcl-2",
398,Development_Self-renewal of adult neural stem cells,52,3.389E-01,7.887E-01,3.389E-01,7.887E-01,2,"PTEN, SOX2",6.908E-01,8.219E-01,1,SOX2,
399,Membrane-bound ESR1: interaction with G-proteins signaling,54,3.393E-01,7.905E-01,3.557E-01,7.905E-01,2,"ESR1 (membrane), Adenylate cyclase",3.393E-01,8.219E-01,2,"ESR1 (membrane), Adenylate cyclase",
400,Eosinophil granule protein release in asthma,54,3.393E-01,7.905E-01,3.557E-01,7.905E-01,2,"Tryptase, CAMP",3.393E-01,8.219E-01,2,"Tryptase, CAMP",
401,Ganglioside Metabolism p1,54,3.393E-01,7.905E-01,3.557E-01,7.905E-01,2,"NEU4, GM3 synthase",3.393E-01,8.219E-01,2,"NEU4, GM3 synthase",
402,Development_Differentiation of white adipocytes ,54,3.393E-01,7.905E-01,3.557E-01,7.905E-01,2,"Perilipin, C/EBPalpha",3.393E-01,8.219E-01,2,"Perilipin, C/EBPalpha",
403,Signal transduction_CXCR4 signaling via MAPKs cascades,53,3.473E-01,7.887E-01,3.473E-01,7.887E-01,2,"N-Ras, PREX1",6.977E-01,8.219E-01,1,PREX1,
404,Development_Role of growth factors in the maintenance of embryonic stem cell pluripotency,53,3.473E-01,7.887E-01,3.473E-01,7.887E-01,2,"SOX2, ErbB3",6.977E-01,8.219E-01,1,SOX2,
405,Cell cycle_Influence of Ras and Rho proteins on G1/S Transition,53,3.473E-01,7.887E-01,3.473E-01,7.887E-01,2,"p27KIP1, Tob1",6.977E-01,8.219E-01,1,Tob1,
406,Role of IL-8 in colorectal cancer,19,3.484E-01,7.905E-01,3.588E-01,7.905E-01,1,IL8RA,3.484E-01,8.219E-01,1,IL8RA,
407,Development_Schema: Adult neurogenesis in the Subventricular Zone,19,3.484E-01,7.905E-01,3.588E-01,7.905E-01,1,TY3H,3.484E-01,8.219E-01,1,TY3H,
408,Regulation of lipid metabolism_Regulation of acetyl-CoA carboxylase 2 activity in muscle,19,3.484E-01,7.905E-01,3.588E-01,7.905E-01,1,ACACB,3.484E-01,8.219E-01,1,ACACB,
409,Protein folding_Membrane trafficking and signal transduction of G-alpha (i) heterotrimeric G-protein,19,3.484E-01,7.905E-01,3.588E-01,7.905E-01,1,Adenylate cyclase type II,3.484E-01,8.219E-01,1,Adenylate cyclase type II,
410,Apoptosis and survival_Endoplasmic reticulum stress response pathway,56,3.556E-01,7.986E-01,3.724E-01,7.986E-01,2,"XBP1, Bcl-2",3.556E-01,8.219E-01,2,"XBP1, Bcl-2",
411,Airway smooth muscle contraction in asthma,56,3.556E-01,7.986E-01,3.724E-01,7.986E-01,2,"BDKRB2, Adenylate cyclase",3.556E-01,8.219E-01,2,"BDKRB2, Adenylate cyclase",
412,Development_YAP/TAZ-mediated co-regulation of transcription,56,3.556E-01,7.986E-01,3.724E-01,7.986E-01,2,"SOX2, GATA-3",3.556E-01,8.219E-01,2,"SOX2, GATA-3",
413,"Disruption of apoptosis, proliferation and shedding of epithelial cells in asthma",54,3.557E-01,7.905E-01,3.557E-01,7.905E-01,2,"p27KIP1, Bcl-2",7.045E-01,8.219E-01,1,Bcl-2,
414,Noise-induced hair cell death and spiral ganglion neuron degeneration,96,3.612E-01,7.986E-01,3.830E-01,7.986E-01,3,"CACNA1I, GFRalpha1, CACNA1D",3.612E-01,8.219E-01,3,"CACNA1I, GFRalpha1, CACNA1D",
415,Role of Langerin+ dermal dendritic cells in contact hypersensitivity,20,3.629E-01,7.986E-01,3.737E-01,7.986E-01,1,FLT3,3.629E-01,8.219E-01,1,FLT3,
416,Role of XBP1 protein in multiple myeloma,20,3.629E-01,7.986E-01,3.737E-01,7.986E-01,1,XBP1,3.629E-01,8.219E-01,1,XBP1,
417,wtCFTR and deltaF508-CFTR traffic / Clathrin coated vesicles formation (normal and CF),20,3.629E-01,7.986E-01,3.737E-01,7.986E-01,1,Myosin I,3.629E-01,8.219E-01,1,Myosin I,
418,Role of nicotine in pathogenesis of SCLC,57,3.637E-01,7.986E-01,3.807E-01,7.986E-01,2,"GRP-R, Bcl-2",3.637E-01,8.219E-01,2,"GRP-R, Bcl-2",
419,Regulation of intrinsic membrane properties and excitability of striatopallidal medium spiny neurons in Huntington's disease,57,3.637E-01,7.986E-01,3.807E-01,7.986E-01,2,"MaxiK alpha subunit, CACNA1D",3.637E-01,8.219E-01,2,"MaxiK alpha subunit, CACNA1D",
420,Aberrant B-Raf signaling in melanoma progression,55,3.641E-01,7.966E-01,3.641E-01,7.966E-01,2,"Tuberin, Bcl-2",7.111E-01,8.219E-01,1,Bcl-2,
421,Immune response_IL-16 signaling pathway,55,3.641E-01,7.966E-01,3.641E-01,7.966E-01,2,"p27KIP1, CCR5",7.111E-01,8.219E-01,1,CCR5,
422,Role of Thyroid hormone in regulation of oligodendrocyte differentiation in multiple sclerosis,55,3.641E-01,7.966E-01,3.641E-01,7.966E-01,2,"p27KIP1, OATP-A",7.111E-01,8.219E-01,1,OATP-A,
423,Macrophage-induced immunosuppression in the tumor microenvironment,97,3.673E-01,7.986E-01,3.893E-01,7.986E-01,3,"ALOX15B, CCR8, CAT-2",3.673E-01,8.219E-01,3,"ALOX15B, CCR8, CAT-2",
424,Immune response_IFN-alpha/beta signaling via PI3K and NF-kB pathways,94,3.704E-01,7.986E-01,3.704E-01,7.986E-01,3,"Tuberin, p27KIP1, PDCD4",8.807E-01,8.890E-01,1,PDCD4,
425,Hyaluronic acid/ CD44 signaling in cancer,58,3.717E-01,7.986E-01,3.890E-01,7.986E-01,2,"ESR1 (nuclear), PDCD4",3.717E-01,8.219E-01,2,"ESR1 (nuclear), PDCD4",
426,Development_Prolactin receptor signaling,58,3.717E-01,7.986E-01,3.890E-01,7.986E-01,2,"Bcl-2, Prolactin receptor",3.717E-01,8.219E-01,2,"Bcl-2, Prolactin receptor",
427,Immune response_CCR5 signaling in macrophages and T lymphocytes,58,3.717E-01,7.986E-01,3.890E-01,7.986E-01,2,"PI3K reg class IB (p101), CCR5",3.717E-01,8.219E-01,2,"PI3K reg class IB (p101), CCR5",
428,Cytoskeleton remodeling_Regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases,58,3.717E-01,7.986E-01,3.890E-01,7.986E-01,2,"RhoA-related, RhoB",3.717E-01,8.219E-01,2,"RhoA-related, RhoB",
429,Role of prenatal nicotine exposure in inhibition of pancreatic beta cells differentiation and function,21,3.771E-01,7.986E-01,3.882E-01,7.986E-01,1,Kir6.2,3.771E-01,8.219E-01,1,Kir6.2,
430,Development_Generation of pancreatic beta-cells from embryonic stem cells (early stages),21,3.771E-01,7.986E-01,3.882E-01,7.986E-01,1,SOX2,3.771E-01,8.219E-01,1,SOX2,
431,Gamma-secretase regulation of mammary cell development,21,3.771E-01,7.986E-01,3.882E-01,7.986E-01,1,MTG16 (CBFA2T3),3.771E-01,8.219E-01,1,MTG16 (CBFA2T3),
432,Nicotine signaling (general schema),21,3.771E-01,7.986E-01,3.882E-01,7.986E-01,1,nAChR alpha-4,3.771E-01,8.219E-01,1,nAChR alpha-4,
433,Inflammatory response in ischemia-reperfusion injury during myocardial infarction,21,3.771E-01,7.986E-01,3.882E-01,7.986E-01,1,IL8RA,3.771E-01,8.219E-01,1,IL8RA,
434,Possible regulation of HSF-1/ chaperone pathway in Huntington's disease,21,3.771E-01,7.986E-01,3.882E-01,7.986E-01,1,PLA2,3.771E-01,8.219E-01,1,PLA2,
435,Oxidative stress_Activation of NADPH oxidase,59,3.797E-01,8.064E-01,3.972E-01,8.064E-01,2,"PI3K reg class IB (p101), PREX1",3.797E-01,8.219E-01,2,"PI3K reg class IB (p101), PREX1",
436,Neurophysiological process_Constitutive and activity-dependent synaptic AMPA receptor delivery,59,3.797E-01,8.064E-01,3.972E-01,8.064E-01,2,"Complexin, Chapsyn-110",3.797E-01,8.219E-01,2,"Complexin, Chapsyn-110",
437,Development_Cytokine-mediated regulation of megakaryopoiesis,57,3.807E-01,7.986E-01,3.807E-01,7.986E-01,2,"p27KIP1, FLT3",7.239E-01,8.222E-01,1,FLT3,
438,Cytoskeleton remodeling_FAK signaling,57,3.807E-01,7.986E-01,3.807E-01,7.986E-01,2,"PTEN, GRP-R",7.239E-01,8.222E-01,1,GRP-R,
439,Apoptotic pathways and resistance to apoptosis in lung cancer cells,57,3.807E-01,7.986E-01,3.807E-01,7.986E-01,2,"p27KIP1, Bcl-2",7.239E-01,8.222E-01,1,Bcl-2,
440,Skeletal muscle atrophy in COPD,57,3.807E-01,7.986E-01,3.807E-01,7.986E-01,2,"MYBPC1, Tuberin",7.239E-01,8.222E-01,1,MYBPC1,
441,Tumor metabolic pathways promoting development of Treg cells,96,3.830E-01,7.986E-01,3.830E-01,7.986E-01,3,"PDK1, FASN, CCR5",8.860E-01,8.933E-01,1,CCR5,
442,Immune response_IL-17 signaling pathways,60,3.876E-01,8.072E-01,4.053E-01,8.072E-01,2,"Mucin 5B, Mucin 5AC",3.876E-01,8.219E-01,2,"Mucin 5B, Mucin 5AC",
443,Immune response_ICOS signaling pathway in T-helper cell,60,3.876E-01,8.072E-01,4.053E-01,8.072E-01,2,"ROR-gamma, KLF2",3.876E-01,8.219E-01,2,"ROR-gamma, KLF2",
444,Immune response_LTBR1 signaling,60,3.876E-01,8.072E-01,4.053E-01,8.072E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",3.876E-01,8.219E-01,2,"PI3K reg class IB (p101), Adenylate cyclase",
445,Development_Dopamine-induced expression of CNTF in adult neurogenesis,22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,Adenylate cyclase type V,3.910E-01,8.219E-01,1,Adenylate cyclase type V,
446,Expression targets of Tissue factor signaling in cancer,22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,Coagulation factor VII,3.910E-01,8.219E-01,1,Coagulation factor VII,
447,Immune response_IL-15 signaling via JAK-STAT cascade,22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,Bcl-2,3.910E-01,8.219E-01,1,Bcl-2,
448,Origin of Langerhans cells in the steady-state and under inflammatory conditions,22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,CXCL14,3.910E-01,8.219E-01,1,CXCL14,
449,Ubiquitin-proteasome system in Huntington's disease,22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,NR1,3.910E-01,8.219E-01,1,NR1,
450,Inhibition of GSK3 beta by lithium in major depressive disorder,22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,Bcl-2,3.910E-01,8.219E-01,1,Bcl-2,
451,Development_Generation of pancreatic beta-cells from embryonic stem cells (late stages),22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,Nkx2.2,3.910E-01,8.219E-01,1,Nkx2.2,
452,LRRK2 and immune function in Parkinson's disease,22,3.910E-01,8.064E-01,4.023E-01,8.064E-01,1,LRRK2,3.910E-01,8.219E-01,1,LRRK2,
453,n-6 Polyunsaturated fatty acid biosynthesis,61,3.955E-01,8.084E-01,4.134E-01,8.084E-01,2,"ELOVL2, ACOX2",3.955E-01,8.219E-01,2,"ELOVL2, ACOX2",
454,Neolacto-series GSL Metabolism p.2,61,3.955E-01,8.084E-01,4.134E-01,8.084E-01,2,"GALGT2, CHST1",3.955E-01,8.219E-01,2,"GALGT2, CHST1",
455,Inhibition of apoptosis in pancreatic cancer,59,3.972E-01,8.064E-01,3.972E-01,8.064E-01,2,"PTEN, Bcl-2",7.361E-01,8.231E-01,1,Bcl-2,
456,Signal transduction_Adenosine A1 receptor signaling pathway,62,4.034E-01,8.084E-01,4.214E-01,8.084E-01,2,"SFK, Adenylate cyclase",4.034E-01,8.219E-01,2,"SFK, Adenylate cyclase",
457,Heme metabolism,103,4.036E-01,8.084E-01,4.266E-01,8.084E-01,3,"UGT2B28, UGT2B17, CYP2B6",4.036E-01,8.219E-01,3,"UGT2B28, UGT2B17, CYP2B6",
458,Role of alpha-V/ beta-6 integrin in colorectal cancer,23,4.046E-01,8.084E-01,4.162E-01,8.084E-01,1,Bcl-2,4.046E-01,8.219E-01,1,Bcl-2,
459,Apoptosis and survival_Beta-2 adrenergic receptor anti-apoptotic action,23,4.046E-01,8.084E-01,4.162E-01,8.084E-01,1,PI3K reg class IB (p101),4.046E-01,8.219E-01,1,PI3K reg class IB (p101),
460,FGF signaling in gastric cancer,23,4.046E-01,8.084E-01,4.162E-01,8.084E-01,1,FGFR4,4.046E-01,8.219E-01,1,FGFR4,
461,Propionate metabolism p.2,63,4.112E-01,8.084E-01,4.294E-01,8.084E-01,2,"GABT, ACACB",4.112E-01,8.219E-01,2,"GABT, ACACB",
462,n-3 Polyunsaturated fatty acid biosynthesis,63,4.112E-01,8.084E-01,4.294E-01,8.084E-01,2,"ELOVL2, ACOX2",4.112E-01,8.219E-01,2,"ELOVL2, ACOX2",
463,Dual role of TGF-beta 1 in HCC ,24,4.179E-01,8.084E-01,4.297E-01,8.084E-01,1,Bcl-2,4.179E-01,8.219E-01,1,Bcl-2,
464,Mitochondrial ketone bodies biosynthesis and metabolism,24,4.179E-01,8.084E-01,4.297E-01,8.084E-01,1,HMGCS2,4.179E-01,8.219E-01,1,HMGCS2,
465,Development_Regulation of epithelial-to-mesenchymal transition (EMT),64,4.190E-01,8.084E-01,4.373E-01,8.084E-01,2,"TGF-beta 3, Bcl-2",4.190E-01,8.219E-01,2,"TGF-beta 3, Bcl-2",
466,Oxidative stress in adipocyte dysfunction in type 2 diabetes and metabolic syndrome X,64,4.190E-01,8.084E-01,4.373E-01,8.084E-01,2,"Adiponectin, PLA2",4.190E-01,8.219E-01,2,"Adiponectin, PLA2",
467,Immune response_IL-3 signaling via ERK and PI3K,102,4.204E-01,8.084E-01,4.204E-01,8.084E-01,3,"A-Raf-1, p27KIP1, Bcl-2",9.005E-01,9.047E-01,1,Bcl-2,
468,Muscle contraction_Regulation of eNOS activity in endothelial cells,65,4.267E-01,8.084E-01,4.452E-01,8.084E-01,2,"KLF2, BDKRB2",4.267E-01,8.219E-01,2,"KLF2, BDKRB2",
469,Dysregulation of germinal center response in SLE,65,4.267E-01,8.084E-01,4.452E-01,8.084E-01,2,"ESR1 (nuclear), RGS16",4.267E-01,8.219E-01,2,"ESR1 (nuclear), RGS16",
470,Sphingolipid metabolism,107,4.275E-01,8.084E-01,4.510E-01,8.084E-01,3,"DEGS2, ACER1, GM3 synthase",4.275E-01,8.219E-01,3,"DEGS2, ACER1, GM3 synthase",
471,Role of Nicotine-induced Leptin resistance in hypothalamus in development of obesity,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,Thyroliberin,4.309E-01,8.219E-01,1,Thyroliberin,
472,Immune escape mechanisms in Prostate Cancer,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,TGF-beta,4.309E-01,8.219E-01,1,TGF-beta,
473,Putative pathways of activation of monoclonal protein secretion in multiple myeloma,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,XBP1,4.309E-01,8.219E-01,1,XBP1,
474,Immune response_T cell subsets: secreted signals,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,TGF-beta,4.309E-01,8.219E-01,1,TGF-beta,
475,Activation of pro-oncogenic TGF-beta potential in gastric cancer,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,TGF-beta 3,4.309E-01,8.219E-01,1,TGF-beta 3,
476,Cytoskeleton remodeling_Neurofilaments,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,Peripherin,4.309E-01,8.219E-01,1,Peripherin,
477,HSP70 and HSP40-dependent folding in Huntington's disease,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,HSP22,4.309E-01,8.219E-01,1,HSP22,
478,Immune response_IL-2 signaling via JAK/ STAT,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,Bcl-2,4.309E-01,8.219E-01,1,Bcl-2,
479,Dual role of BMP signaling in gastric cancer,25,4.309E-01,8.084E-01,4.429E-01,8.084E-01,1,Mucin 2,4.309E-01,8.219E-01,1,Mucin 2,
480,MAPK-independent proliferation of normal and asthmatic smooth muscle cells,64,4.373E-01,8.084E-01,4.373E-01,8.084E-01,2,"Tryptase, p27KIP1",7.644E-01,8.295E-01,1,Tryptase,
481,Neurogenesis_NGF/ TrkA MAPK-mediated signaling,105,4.388E-01,8.084E-01,4.388E-01,8.084E-01,3,"TY3H, PP2A regulatory, N-Ras",6.827E-01,8.219E-01,2,"TY3H, PP2A regulatory",
482,Hedgehog signaling in prostate cancer,26,4.436E-01,8.084E-01,4.558E-01,8.084E-01,1,Bcl-2,4.436E-01,8.219E-01,1,Bcl-2,
483,Neurophysiological process_GABA-B receptor signaling at postsynaptic sides of synapses,26,4.436E-01,8.084E-01,4.558E-01,8.084E-01,1,Kir3.1,4.436E-01,8.219E-01,1,Kir3.1,
484,Cell adhesion_Endothelial cell contacts by junctional mechanisms,26,4.436E-01,8.084E-01,4.558E-01,8.084E-01,1,Claudin-3,4.436E-01,8.219E-01,1,Claudin-3,
485,CREB1-dependent transcription deregulation in Huntington's Disease,26,4.436E-01,8.084E-01,4.558E-01,8.084E-01,1,Bcl-2,4.436E-01,8.219E-01,1,Bcl-2,
486,"SREBP1 cross-talk with PXR, CAR and LXR",26,4.436E-01,8.084E-01,4.558E-01,8.084E-01,1,CYP2B6,4.436E-01,8.219E-01,1,CYP2B6,
487,Muscle contraction_Delta-type opioid receptor in smooth muscle contraction,26,4.436E-01,8.084E-01,4.558E-01,8.084E-01,1,PI3K reg class IB (p101),4.436E-01,8.219E-01,1,PI3K reg class IB (p101),
488,Signal transduction_HTR2A-dependent arachidonic acid production,26,4.436E-01,8.084E-01,4.558E-01,8.084E-01,1,RhoA-related,4.436E-01,8.219E-01,1,RhoA-related,
489,Activation of osteoclast differentiation in bone lesions formation in multiple myeloma,27,4.560E-01,8.084E-01,4.684E-01,8.084E-01,1,CCR5,4.560E-01,8.219E-01,1,CCR5,
490,Histamine metabolism,27,4.560E-01,8.084E-01,4.684E-01,8.084E-01,1,ABP1,4.560E-01,8.219E-01,1,ABP1,
491,Neurophysiological process_GABA-A receptor life cycle,27,4.560E-01,8.084E-01,4.684E-01,8.084E-01,1,GABA-A receptor gamma-2 subunit,4.560E-01,8.219E-01,1,GABA-A receptor gamma-2 subunit,
492,Inhibition of TGF-beta 1 signaling in early colorectal cancer,27,4.560E-01,8.084E-01,4.684E-01,8.084E-01,1,CEACAM5,4.560E-01,8.219E-01,1,CEACAM5,
493,Desensitization of Beta-2 adrenergic receptor signaling and reduction of relaxation,27,4.560E-01,8.084E-01,4.684E-01,8.084E-01,1,PGE2R3,4.560E-01,8.219E-01,1,PGE2R3,
494,Calcium-dependent regulation of normal and asthmatic smooth muscle contraction,69,4.569E-01,8.084E-01,4.760E-01,8.084E-01,2,"Tryptase, BDKRB2",4.569E-01,8.219E-01,2,"Tryptase, BDKRB2",
495,Chemotaxis_CXCR3-A signaling,69,4.569E-01,8.084E-01,4.760E-01,8.084E-01,2,"PI3K reg class IB (p101), ROR-gamma",4.569E-01,8.219E-01,2,"PI3K reg class IB (p101), ROR-gamma",
496,ErbB2-induced breast cancer cell invasion,67,4.607E-01,8.084E-01,4.607E-01,8.084E-01,2,"PDCD4, ErbB3",7.798E-01,8.336E-01,1,PDCD4,
497,Immune response_IL-11 signaling pathway via MEK/ERK and PI3K/AKT cascades,67,4.607E-01,8.084E-01,4.607E-01,8.084E-01,2,"SFK, p27KIP1",7.798E-01,8.336E-01,1,SFK,
498,Neurophysiological process_Role of CDK5 in presynaptic signaling,28,4.682E-01,8.084E-01,4.807E-01,8.084E-01,1,TY3H,4.682E-01,8.219E-01,1,TY3H,
499,Neurophysiological process_GABA-B receptor signaling in presynaptic nerve terminals,28,4.682E-01,8.084E-01,4.807E-01,8.084E-01,1,Adenylate cyclase type V,4.682E-01,8.219E-01,1,Adenylate cyclase type V,
500,Pro-oncogenic action of Androgen receptor in ovarian cancer,28,4.682E-01,8.084E-01,4.807E-01,8.084E-01,1,Androgen receptor,4.682E-01,8.219E-01,1,Androgen receptor,
501,Mitogenic action of Estradiol / ESR1 (nuclear) in breast cancer,28,4.682E-01,8.084E-01,4.807E-01,8.084E-01,1,ESR1 (nuclear),4.682E-01,8.219E-01,1,ESR1 (nuclear),
502,Development_Regulation of CDK5 in CNS,28,4.682E-01,8.084E-01,4.807E-01,8.084E-01,1,Adenylate cyclase type V,4.682E-01,8.219E-01,1,Adenylate cyclase type V,
503,IL-17 and IL-17F-induced inflammatory signaling in normal and asthmatic airway epithelium,28,4.682E-01,8.084E-01,4.807E-01,8.084E-01,1,IL-19,4.682E-01,8.219E-01,1,IL-19,
504,Development_Positive regulation of STK3/4 (Hippo) pathway and negative regulation of YAP/TAZ function,71,4.717E-01,8.084E-01,4.910E-01,8.084E-01,2,"EBP50, Adenylate cyclase",4.717E-01,8.219E-01,2,"EBP50, Adenylate cyclase",
505,Role of microRNAs in cell proliferation in colorectal cancer,69,4.760E-01,8.084E-01,4.760E-01,8.084E-01,2,"PTEN, RhoB",7.896E-01,8.377E-01,1,RhoB,
506,Hedgehog signaling in gastric cancer,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,MSX-2,4.800E-01,8.219E-01,1,MSX-2,
507,Bone metastases in Prostate Cancer,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,PTHR1,4.800E-01,8.219E-01,1,PTHR1,
508,Histone deacetylases in Prostate Cancer,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,Androgen receptor,4.800E-01,8.219E-01,1,Androgen receptor,
509,Apoptosis and survival_p53-dependent apoptosis,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,Bcl-2,4.800E-01,8.219E-01,1,Bcl-2,
510,EZH2 in Prostate Cancer,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,PGE2R3,4.800E-01,8.219E-01,1,PGE2R3,
511,Immune response_Delta-type opioid receptor signaling in T-cells,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,PI3K reg class IB (p101),4.800E-01,8.219E-01,1,PI3K reg class IB (p101),
512,Cholesterol and Sphingolipid transport / Recycling to plasma membrane in lung (normal and CF),29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,ABCG1,4.800E-01,8.219E-01,1,ABCG1,
513,Development_SSTR1 in regulation of cell proliferation and migration,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,PI3K reg class IB (p101),4.800E-01,8.219E-01,1,PI3K reg class IB (p101),
514,Immune response_CD137 signaling in immune cell,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,Bcl-2,4.800E-01,8.219E-01,1,Bcl-2,
515,Prostate Cancer: candidate susceptibility genes in inflammatory pathways,29,4.800E-01,8.084E-01,4.927E-01,8.084E-01,1,IL8RA,4.800E-01,8.219E-01,1,IL8RA,
516,Signal transduction_Adenosine A2B receptor signaling pathway,71,4.910E-01,8.084E-01,4.910E-01,8.084E-01,2,"PDK1, Adenylate cyclase",7.989E-01,8.424E-01,1,Adenylate cyclase,
517,Inhibition of mast cell functions by Siglecs in asthma,30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,SIGLEC5,4.917E-01,8.219E-01,1,SIGLEC5,
518,Development_WNT/Beta-catenin signaling in cell differentiation,30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,ROR-gamma,4.917E-01,8.219E-01,1,ROR-gamma,
519,"Regulation of lipid metabolism_RXR-dependent regulation of lipid metabolism via PPAR, RAR and VDR",30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,HMGCS2,4.917E-01,8.219E-01,1,HMGCS2,
520,Putative role of Tregs in COPD,30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,ROR-gamma,4.917E-01,8.219E-01,1,ROR-gamma,
521,Cell adhesion_Gap junctions,30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,Connexin 32,4.917E-01,8.219E-01,1,Connexin 32,
522,Colorectal cancer (general schema),30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,IL8RA,4.917E-01,8.219E-01,1,IL8RA,
523,Production of arachidonic acid derivatives by mast cells in asthma,30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,PLA2(hGIIA),4.917E-01,8.219E-01,1,PLA2(hGIIA),
524,Neurophysiological process_nNOS signaling in neuronal synapses,30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,Dexras1,4.917E-01,8.219E-01,1,Dexras1,
525,Signal transduction_Additional pathways of NF-kB activation (in the nucleus),30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,Adenylate cyclase,4.917E-01,8.219E-01,1,Adenylate cyclase,
526,Inter-cellular relations in COPD (general schema),30,4.917E-01,8.084E-01,5.045E-01,8.084E-01,1,TGF-beta,4.917E-01,8.219E-01,1,TGF-beta,
527,Metabolism of L-Proline and derivatives,74,4.935E-01,8.084E-01,5.130E-01,8.084E-01,2,"CRYM, DHDPSL",4.935E-01,8.219E-01,2,"CRYM, DHDPSL",
528,Arachidonic acid production,74,4.935E-01,8.084E-01,5.130E-01,8.084E-01,2,"PLA2(hGIIA), PLC-eta 2",4.935E-01,8.219E-01,2,"PLA2(hGIIA), PLC-eta 2",
529,Renal secretion of organic electrolytes / Rodent version ,75,5.006E-01,8.084E-01,5.202E-01,8.084E-01,2,"SLC5A8, PEPT1",5.006E-01,8.219E-01,2,"SLC5A8, PEPT1",
530,"SREBP1 cross-talk with PXR, CAR and LXR/ Rodent version",31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,CYP2B6,5.030E-01,8.219E-01,1,CYP2B6,
531,Role of IL-2 in the enhancement of NK cell cytotoxicity in multiple sclerosis,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,CX3CR1,5.030E-01,8.219E-01,1,CX3CR1,
532,Deregulation of canonical WNT signaling in major depressive disorder,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,Tau (MAPT),5.030E-01,8.219E-01,1,Tau (MAPT),
533,SHH signaling in colorectal cancer,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,Bcl-2,5.030E-01,8.219E-01,1,Bcl-2,
534,Development_Activation of ERK by Kappa-type opioid receptor,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,PI3K reg class IB (p101),5.030E-01,8.219E-01,1,PI3K reg class IB (p101),
535,Apoptosis and survival_Role of IAP-proteins in apoptosis,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,NAIP,5.030E-01,8.219E-01,1,NAIP,
536,Arachidonic acid metabolites production in alveolar macrophages in asthma,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,PLA2(hGIIA),5.030E-01,8.219E-01,1,PLA2(hGIIA),
537,Putative glucocorticoid- and LABA-mediated inhibition of pro-fibrotic signaling in airway fibroblasts/myofibroblasts,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,C/EBPalpha,5.030E-01,8.219E-01,1,C/EBPalpha,
538,Influence of low doses of Arsenite on glucose uptake in adipocytes,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,C/EBPalpha,5.030E-01,8.219E-01,1,C/EBPalpha,
539,Immune response_IL-23 signaling pathway,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,ROR-gamma,5.030E-01,8.219E-01,1,ROR-gamma,
540,NETosis in SLE,31,5.030E-01,8.084E-01,5.160E-01,8.084E-01,1,CAMP,5.030E-01,8.219E-01,1,CAMP,
541,"Immune response_IL-2 signaling via ERK, PI3K, and PLC-gamma",73,5.057E-01,8.084E-01,5.057E-01,8.084E-01,2,"p27KIP1, Bcl-2",8.078E-01,8.438E-01,1,Bcl-2,
542,Signal transduction_mTORC1 upstream signaling,74,5.130E-01,8.084E-01,5.130E-01,8.084E-01,2,"Tuberin, GHR",8.121E-01,8.438E-01,1,GHR,
543,Immune response_Distinct metabolic pathways in naive and effector CD8+ T cells,74,5.130E-01,8.084E-01,5.130E-01,8.084E-01,2,"Tuberin, DHE4",8.121E-01,8.438E-01,1,DHE4,
544,Development_Transcription regulation of granulocyte development,32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,C/EBPalpha,5.141E-01,8.219E-01,1,C/EBPalpha,
545,"Stem cells_Cooperation between Hedgehog, IGF-2 and HGF signaling pathways in medulloblastoma stem cells",32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,Bcl-2,5.141E-01,8.219E-01,1,Bcl-2,
546,Stem cells_Role of ion channels in glioblastoma cell invasion,32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,MaxiK alpha subunit,5.141E-01,8.219E-01,1,MaxiK alpha subunit,
547,Hedgehog signaling in pancreatic cancer,32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,Bcl-2,5.141E-01,8.219E-01,1,Bcl-2,
548,Protein folding and maturation_Bradykinin / Kallidin maturation,32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,BDKRB2,5.141E-01,8.219E-01,1,BDKRB2,
549,Cytoskeleton remodeling_Reverse signaling by Ephrin-B,32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,Tau (MAPT),5.141E-01,8.219E-01,1,Tau (MAPT),
550,Epithelial cell apoptosis in COPD,32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,Bcl-2,5.141E-01,8.219E-01,1,Bcl-2,
551,"Development_Role of Ceramide 1-phosphate, Sphingosine 1-phosphate and Complement cascade in hematopoietic stem cell homing",32,5.141E-01,8.084E-01,5.272E-01,8.084E-01,1,PGE2R3,5.141E-01,8.219E-01,1,PGE2R3,
552,Role of metalloproteases and heparanase in progression of pancreatic cancer,33,5.250E-01,8.084E-01,5.381E-01,8.084E-01,1,Alpha 1-antitrypsin,5.250E-01,8.219E-01,1,Alpha 1-antitrypsin,
553,Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins,33,5.250E-01,8.084E-01,5.381E-01,8.084E-01,1,Bcl-2,5.250E-01,8.219E-01,1,Bcl-2,
554,Influence of multiple myeloma cells on bone marrow stromal cells,33,5.250E-01,8.084E-01,5.381E-01,8.084E-01,1,FGFR4,5.250E-01,8.219E-01,1,FGFR4,
555,Chemotaxis_CCL19- and CCL21-mediated chemotaxis,33,5.250E-01,8.084E-01,5.381E-01,8.084E-01,1,Adenylate cyclase,5.250E-01,8.219E-01,1,Adenylate cyclase,
556,"Leucine, isoleucine and valine metabolism.p.2",79,5.284E-01,8.084E-01,5.483E-01,8.084E-01,2,"GABT, HMGCS2",5.284E-01,8.219E-01,2,"GABT, HMGCS2",
557,Chemotaxis_SDF-1/ CXCR4-induced chemotaxis of immune cells,79,5.284E-01,8.084E-01,5.483E-01,8.084E-01,2,"SFK, PI3K reg class IB (p101)",5.284E-01,8.219E-01,2,"SFK, PI3K reg class IB (p101)",
558,L-Tryptophan metabolism (part 1),80,5.352E-01,8.084E-01,5.551E-01,8.084E-01,2,"SLC7A8, INMT",5.352E-01,8.219E-01,2,"SLC7A8, INMT",
559,Signal transduction_Erk Interactions: Inhibition of Erk,34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,MKP-2,5.356E-01,8.219E-01,1,MKP-2,
560,Regulation of CFTR gating (normal and CF),34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,Adenylate cyclase,5.356E-01,8.219E-01,1,Adenylate cyclase,
561,Cannabinoid receptor signaling in nicotine addiction,34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,nAChR alpha-4,5.356E-01,8.219E-01,1,nAChR alpha-4,
562,Immune response_IL-11 signaling via JAK/STAT,34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,Bcl-2,5.356E-01,8.219E-01,1,Bcl-2,
563,Oxidative stress_ROS-mediated activation of MAPK via inhibition of phosphatases,34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,PP2A regulatory,5.356E-01,8.219E-01,1,PP2A regulatory,
564,"Apoptosis and survival_Cytoplasmic/mitochondrial transport of proapoptotic proteins Bid, Bmf and Bim",34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,Bcl-2,5.356E-01,8.219E-01,1,Bcl-2,
565,NK cells in allergic contact dermatitis,34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,CCR5,5.356E-01,8.219E-01,1,CCR5,
566,Development_Role of cell-cell and ECM-cell interactions in oligodendrocyte differentiation and myelination,34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,Connexin 32,5.356E-01,8.219E-01,1,Connexin 32,
567,Role of Apo-2L(TNFSF10) in Prostate Cancer cell apoptosis,34,5.356E-01,8.084E-01,5.488E-01,8.084E-01,1,Bcl-2,5.356E-01,8.219E-01,1,Bcl-2,
568,Role of osteoblasts in bone lesions formation in multiple myeloma,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,CCR5,5.459E-01,8.219E-01,1,CCR5,
569,Immune response_Th17 cell differentiation,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,ROR-gamma,5.459E-01,8.219E-01,1,ROR-gamma,
570,TNF-alpha and IL-1 beta induce hyperglycemia in obesity and type 2 diabetes in adipocytes,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,GM3 synthase,5.459E-01,8.219E-01,1,GM3 synthase,
571,Anti-apoptotic action of Gastrin in gastric cancer,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,Bcl-2,5.459E-01,8.219E-01,1,Bcl-2,
572,Altered Ca2+ handling in heart failure,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,Adenylate cyclase,5.459E-01,8.219E-01,1,Adenylate cyclase,
573,Role of Tissue factor in cancer independent of coagulation protease signaling,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,Coagulation factor VII,5.459E-01,8.219E-01,1,Coagulation factor VII,
574,NF-kB pathway in multiple myeloma,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,Bcl-2,5.459E-01,8.219E-01,1,Bcl-2,
575,Keratan sulfate metabolism p.1,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,CHST1,5.459E-01,8.219E-01,1,CHST1,
576,Immune response_Lipoxins and Resolvin E1 inhibitory action on neutrophil functions,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,PI3K reg class IB (p101),5.459E-01,8.219E-01,1,PI3K reg class IB (p101),
577,Development_Growth hormone signaling via STATs and PLC/IP3,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,GHR,5.459E-01,8.219E-01,1,GHR,
578,Anti-apoptotic action of Gastrin in pancreatic cancer,35,5.459E-01,8.084E-01,5.593E-01,8.084E-01,1,Bcl-2,5.459E-01,8.219E-01,1,Bcl-2,
579,Chemotaxis_Lysophosphatidic acid signaling via GPCRs,129,5.512E-01,8.084E-01,5.762E-01,8.084E-01,3,"Rho GTPase, Bcl-2, PREX1",5.512E-01,8.219E-01,3,"Rho GTPase, Bcl-2, PREX1",
580,Muscle contraction_GPCRs in the regulation of smooth muscle tone,83,5.551E-01,8.084E-01,5.752E-01,8.084E-01,2,"MaxiK alpha subunit, Adenylate cyclase",5.551E-01,8.219E-01,2,"MaxiK alpha subunit, Adenylate cyclase",
581,Cytoskeleton remodeling_Keratin filaments,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Keratin 2,5.561E-01,8.219E-01,1,Keratin 2,
582,Prolactin/ ERK signaling in breast cancer,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Prolactin receptor,5.561E-01,8.219E-01,1,Prolactin receptor,
583,Immune response_IL-6-induced acute-phase response in hepatocytes,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Hemopexin,5.561E-01,8.219E-01,1,Hemopexin,
584,Endothelial cell apoptosis in COPD,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Bcl-2,5.561E-01,8.219E-01,1,Bcl-2,
585,HBV signaling via protein kinases leading to HCC,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Androgen receptor,5.561E-01,8.219E-01,1,Androgen receptor,
586,Cigarette smoke components TCDD and Benzo[a]pyrene and receptor AHR signaling in lung epithelial cells,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Mucin 5AC,5.561E-01,8.219E-01,1,Mucin 5AC,
587,Role of IL-8 in melanoma,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,IL8RA,5.561E-01,8.219E-01,1,IL8RA,
588,G-protein signaling_Rac2 regulation pathway,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,PREX1,5.561E-01,8.219E-01,1,PREX1,
589,Inhibition of apoptosis in multiple myeloma,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Bcl-2,5.561E-01,8.219E-01,1,Bcl-2,
590,Development_Hedgehog and PTH signaling pathways in bone and cartilage development,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,PTHR1,5.561E-01,8.219E-01,1,PTHR1,
591,Immune response_IL-22 signaling pathway,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Bcl-2,5.561E-01,8.219E-01,1,Bcl-2,
592,Immune response_IL-12-induced IFN-gamma production,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,GADD45 gamma,5.561E-01,8.219E-01,1,GADD45 gamma,
593,"Development_Lipoxin inhibitory action on PDGF, EGF and LTD4 signaling",36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Adenylate cyclase,5.561E-01,8.219E-01,1,Adenylate cyclase,
594,Development_Thrombospondin 1 signaling,36,5.561E-01,8.084E-01,5.695E-01,8.084E-01,1,Adenylate cyclase,5.561E-01,8.219E-01,1,Adenylate cyclase,
595,Transcription_CoREST complex-mediated epigenetic gene silencing,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,NR1,5.660E-01,8.219E-01,1,NR1,
596,Development_Delta-type opioid receptor mediated cardioprotection,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,Kir6.2,5.660E-01,8.219E-01,1,Kir6.2,
597,Immune response_Generation of memory CD4+ T cells,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,Bcl-2,5.660E-01,8.219E-01,1,Bcl-2,
598,G-protein signaling_H-RAS regulation pathway,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,GFRalpha1,5.660E-01,8.219E-01,1,GFRalpha1,
599,Development_Negative feedback regulation of WNT/Beta-catenin signaling,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,ZNF703,5.660E-01,8.219E-01,1,ZNF703,
600,G-protein signaling_Regulation of p38 and JNK signaling mediated by G-proteins,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,PI3K reg class IB (p101),5.660E-01,8.219E-01,1,PI3K reg class IB (p101),
601,G-protein signaling_RAC1 in cellular process,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,POR1,5.660E-01,8.219E-01,1,POR1,
602,Deregulation of PSD-95-dependent signaling in Huntington's disease,37,5.660E-01,8.084E-01,5.795E-01,8.084E-01,1,NR1,5.660E-01,8.219E-01,1,NR1,
603,Development_Negative regulation of WNT/Beta-catenin signaling in the cytoplasm,82,5.686E-01,8.084E-01,5.686E-01,8.084E-01,2,"CXXC4, Beclin 1",8.433E-01,8.635E-01,1,CXXC4,
604,Glycine and L-Serine metabolism,133,5.720E-01,8.084E-01,5.970E-01,8.084E-01,3,"SLC7A8, GNMT, AGXT",5.720E-01,8.219E-01,3,"SLC7A8, GNMT, AGXT",
605,Role of type 2 innate lymphoid cells in airway allergic inflammation and tissue repair,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,GATA-3,5.757E-01,8.219E-01,1,GATA-3,
606,wtCFTR and deltaF508-CFTR traffic / Generic schema (normal and CF),38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,EBP50,5.757E-01,8.219E-01,1,EBP50,
607,Impaired macrophage phagocytic function in asthma,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,SP-D,5.757E-01,8.219E-01,1,SP-D,
608,Development_Gastrin in differentiation of the gastric mucosa,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,TFF1,5.757E-01,8.219E-01,1,TFF1,
609,HDL dyslipidemia in type 2 diabetes and metabolic syndrome X,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,ABCG1,5.757E-01,8.219E-01,1,ABCG1,
610,Development_Oligodendrocyte differentiation (general schema),38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,Nkx2.2,5.757E-01,8.219E-01,1,Nkx2.2,
611,Transcription_Role of AP-1 in regulation of cellular metabolism,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,CG alpha,5.757E-01,8.219E-01,1,CG alpha,
612,Cortisol biosynthesis from Cholesterol,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,CYP11B2,5.757E-01,8.219E-01,1,CYP11B2,
613,Eosinophil-derived cytokines in airway remodeling in asthma,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,MMP-17,5.757E-01,8.219E-01,1,MMP-17,
614,Aldosterone biosynthesis and metabolism,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,CYP11B2,5.757E-01,8.219E-01,1,CYP11B2,
615,Role of type 2 innate lymphoid cells in asthma,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,GATA-3,5.757E-01,8.219E-01,1,GATA-3,
616,Role of Endothelin-1 in inflammation and vasoconstriction in Sickle cell disease,38,5.757E-01,8.084E-01,5.892E-01,8.084E-01,1,CCR5,5.757E-01,8.219E-01,1,CCR5,
617,HIV-1 signaling via CCR5 in macrophages and T lymphocytes,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,CCR5,5.852E-01,8.219E-01,1,CCR5,
618,Resistance of melanoma cells to Apo-2L(TNFSF10)-induced apoptosis,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,Bcl-2,5.852E-01,8.219E-01,1,Bcl-2,
619,"VLDL, LDL dyslipidemia in type 2 diabetes and metabolic syndrome X",39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,APOB48 receptor,5.852E-01,8.219E-01,1,APOB48 receptor,
620,Signal transduction_Leptin signaling via JAK/STAT and MAPK cascade,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,Thyroliberin,5.852E-01,8.219E-01,1,Thyroliberin,
621,Role of tumor microenvironment in plexiform neurofibroma formation in neurofibromatosis type 1,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,Tryptase,5.852E-01,8.219E-01,1,Tryptase,
622,NRSF-dependent transcription deregulation in Huntington's Disease,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,NR1,5.852E-01,8.219E-01,1,NR1,
623,Role of neurotrophins in activation of p53 in major depressive disorder,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,Bcl-2,5.852E-01,8.219E-01,1,Bcl-2,
624,Transport_Regulation of ATP-binding transporters by Retinoic acid and orphan nuclear receptor PXR,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,ABCG1,5.852E-01,8.219E-01,1,ABCG1,
625,Keratan sulfate metabolism p.2,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,CHST1,5.852E-01,8.219E-01,1,CHST1,
626,Nicotine signaling in GABAergic neurons,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,nAChR alpha-4,5.852E-01,8.219E-01,1,nAChR alpha-4,
627,TrkB signaling in Huntington's disease,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,NR1,5.852E-01,8.219E-01,1,NR1,
628,Apoptosis and survival_APRIL and BAFF signaling,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,Bcl-2,5.852E-01,8.219E-01,1,Bcl-2,
629,Transcription_p53 signaling pathway,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,Bcl-2,5.852E-01,8.219E-01,1,Bcl-2,
630,Butanoic acid metabolism,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,SLC5A8,5.852E-01,8.219E-01,1,SLC5A8,
631,Cooperative action of IFN-gamma and TNF-alpha on astrocytes in multiple sclerosis,39,5.852E-01,8.084E-01,5.987E-01,8.084E-01,1,Adenylate cyclase,5.852E-01,8.219E-01,1,Adenylate cyclase,
632,Development_Negative regulation of WNT/Beta-catenin signaling in the nucleus,89,5.932E-01,8.084E-01,6.133E-01,8.084E-01,2,"ZNF703, SOX2",5.932E-01,8.219E-01,2,"ZNF703, SOX2",
633,Apoptosis and survival_NGF activation of NF-kB,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,Bcl-2,5.944E-01,8.219E-01,1,Bcl-2,
634,CAR-mediated direct regulation of xenobiotic metabolizing enzymes / Rodent version,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,CYP2B6,5.944E-01,8.219E-01,1,CYP2B6,
635,Stem cells_NOTCH1-induced self-renewal of glioblastoma stem cells,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,SOX2,5.944E-01,8.219E-01,1,SOX2,
636,Apoptosis and survival_Ceramides signaling pathway,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,Bcl-2,5.944E-01,8.219E-01,1,Bcl-2,
637,Role of Ghrelin in activation eating behavior in obesity,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,Adenylate cyclase type II,5.944E-01,8.219E-01,1,Adenylate cyclase type II,
638,Development_H3K27 demethylases in differentiation of stem cells,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,HOXB1,5.944E-01,8.219E-01,1,HOXB1,
639,Immune response_Th1 and Th2 cell differentiation,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,GATA-3,5.944E-01,8.219E-01,1,GATA-3,
640,Stem cells_Pancreatic cancer stem cells in tumor metastasis,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,PI3K reg class IB (p101),5.944E-01,8.219E-01,1,PI3K reg class IB (p101),
641,"N-Acylethanolamines, Phospholipase A2 pathway",40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,PLA2(hGIIA),5.944E-01,8.219E-01,1,PLA2(hGIIA),
642,Development_SLIT-ROBO1 signaling,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,PREX1,5.944E-01,8.219E-01,1,PREX1,
643,Development_Astrocyte differentiation from adult stem cells,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,Nkx2.2,5.944E-01,8.219E-01,1,Nkx2.2,
644,Role of glycosphingolipids in inhibition of Insulin signaling,40,5.944E-01,8.084E-01,6.080E-01,8.084E-01,1,GM3 synthase,5.944E-01,8.219E-01,1,GM3 synthase,
645,Development_Growth hormone-releasing hormone (GH-RH) signaling,41,6.035E-01,8.084E-01,6.171E-01,8.084E-01,1,Adenylate cyclase,6.035E-01,8.219E-01,1,Adenylate cyclase,
646,Cytoskeleton remodeling_Role of PKA in cytoskeleton reorganisation,41,6.035E-01,8.084E-01,6.171E-01,8.084E-01,1,Adenylate cyclase,6.035E-01,8.219E-01,1,Adenylate cyclase,
647,Development_Muscle progenitor cell migration in hypaxial myogenesis,41,6.035E-01,8.084E-01,6.171E-01,8.084E-01,1,FGFR4,6.035E-01,8.219E-01,1,FGFR4,
648,Maturation and migration of dendritic cells in skin sensitization,41,6.035E-01,8.084E-01,6.171E-01,8.084E-01,1,MHC class II alpha chain,6.035E-01,8.219E-01,1,MHC class II alpha chain,
649,Apoptosis and survival_Phosphorylation in TNF-alpha-induced NF-kB signaling,41,6.035E-01,8.084E-01,6.171E-01,8.084E-01,1,Adenylate cyclase,6.035E-01,8.219E-01,1,Adenylate cyclase,
650,Fibroblast/ myofibroblast proliferation in asthmatic airways,41,6.035E-01,8.084E-01,6.171E-01,8.084E-01,1,Tryptase,6.035E-01,8.219E-01,1,Tryptase,
651,Stem cells_Inhibition of Hedgehog signaling in medulloblastoma stem cells,41,6.035E-01,8.084E-01,6.171E-01,8.084E-01,1,FGFR4,6.035E-01,8.219E-01,1,FGFR4,
652,Interconnectivity between Folic acid and Fluorouracil pathways in gastric cancer,91,6.054E-01,8.084E-01,6.254E-01,8.084E-01,2,"ABCC11, CYP2A6",6.054E-01,8.219E-01,2,"ABCC11, CYP2A6",
653,Apoptosis and survival_Apoptotic TNF-family pathways,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,Bcl-2,6.124E-01,8.219E-01,1,Bcl-2,
654,Role of TNF-alpha in type 2 diabetes in skeletal muscle cells,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,ACACB,6.124E-01,8.219E-01,1,ACACB,
655,Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,Bcl-2,6.124E-01,8.219E-01,1,Bcl-2,
656,Development_NOTCH in inhibition of WNT/Beta-catenin-induced osteogenesis,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,C/EBPalpha,6.124E-01,8.219E-01,1,C/EBPalpha,
657,Chemoresistance pathways mediated by constitutive activation of PI3K pathway and BCL-2 in small cell lung cancer,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,Bcl-2,6.124E-01,8.219E-01,1,Bcl-2,
658,Development_VEGF signaling and activation,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,ESR1 (nuclear),6.124E-01,8.219E-01,1,ESR1 (nuclear),
659,Chylomicron dyslipidemia in type 2 diabetes and metabolic syndrome X,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,APOB48 receptor,6.124E-01,8.219E-01,1,APOB48 receptor,
660,Disruption of methionine metabolism in induction and progression of HCC,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,GNMT,6.124E-01,8.219E-01,1,GNMT,
661,"TNF-alpha, IL-1 beta induce dyslipidemia and inflammation in obesity and type 2 diabetes in adipocytes ",42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,Perilipin,6.124E-01,8.219E-01,1,Perilipin,
662,Inhibition of apoptosis in gastric cancer,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,Bcl-2,6.124E-01,8.219E-01,1,Bcl-2,
663,Signal transduction_WNT/Beta-catenin signaling in tissue homeostasis,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,ROR-gamma,6.124E-01,8.219E-01,1,ROR-gamma,
664,Transport_HDL-mediated reverse cholesterol transport,42,6.124E-01,8.084E-01,6.260E-01,8.084E-01,1,ABCG1,6.124E-01,8.219E-01,1,ABCG1,
665,Regulation of lipid metabolism_Insulin regulation of fatty acid metabolism,89,6.133E-01,8.084E-01,6.133E-01,8.084E-01,2,"FASN, Perilipin",8.663E-01,8.797E-01,1,Perilipin,
666,L-Lysine metabolism,93,6.172E-01,8.084E-01,6.372E-01,8.084E-01,2,"CRYM, CAT-2",6.172E-01,8.219E-01,2,"CRYM, CAT-2",
667,"NF-kB-, AP-1- and MAPKs-mediated proinflammatory cytokine production by eosinophils in asthma",43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,Tryptase,6.210E-01,8.219E-01,1,Tryptase,
668,"Nicotine signaling in dopaminergic neurons, Pt. 2 - axon terminal",43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,Adenylate cyclase type V,6.210E-01,8.219E-01,1,Adenylate cyclase type V,
669,Impaired inhibitory action of lipoxins and Resolvin E1 on neutrophil functions in CF,43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,PI3K reg class IB (p101),6.210E-01,8.219E-01,1,PI3K reg class IB (p101),
670,Immune response_Antimicrobial actions of IFN-gamma,43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,SLC26A3 (DRA),6.210E-01,8.219E-01,1,SLC26A3 (DRA),
671,Apoptosis and survival_Anti-apoptotic action of Gastrin,43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,Bcl-2,6.210E-01,8.219E-01,1,Bcl-2,
672,Effect of H. pylori infection on gastric epithelial cells motility,43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,Connexin 32,6.210E-01,8.219E-01,1,Connexin 32,
673,Apoptosis and survival_TNFR1 signaling pathway,43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,Bcl-2,6.210E-01,8.219E-01,1,Bcl-2,
674,Apoptosis and survival_TNF-alpha-induced Caspase-8 signaling,43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,PP2A regulatory,6.210E-01,8.219E-01,1,PP2A regulatory,
675,Regulation of immune cell differentiation by Notch signaling,43,6.210E-01,8.084E-01,6.347E-01,8.084E-01,1,GATA-3,6.210E-01,8.219E-01,1,GATA-3,
676,Histidine-glutamate-glutamine metabolism,95,6.288E-01,8.084E-01,6.488E-01,8.084E-01,2,"GABT, DHE4",6.288E-01,8.219E-01,2,"GABT, DHE4",
677,Development_Flt3 signaling,44,6.295E-01,8.084E-01,6.431E-01,8.084E-01,1,FLT3,6.295E-01,8.219E-01,1,FLT3,
678,Apoptosis and survival_FAS signaling cascades,44,6.295E-01,8.084E-01,6.431E-01,8.084E-01,1,Bcl-2,6.295E-01,8.219E-01,1,Bcl-2,
679,Impaired Lipoxin A4 signaling in CF,44,6.295E-01,8.084E-01,6.431E-01,8.084E-01,1,Adenylate cyclase,6.295E-01,8.219E-01,1,Adenylate cyclase,
680,Chemotaxis_C5a-induced chemotaxis,44,6.295E-01,8.084E-01,6.431E-01,8.084E-01,1,PREX1,6.295E-01,8.219E-01,1,PREX1,
681,Influence of smoking on activation of EGFR signaling in lung cancer cells,44,6.295E-01,8.084E-01,6.431E-01,8.084E-01,1,Adenylate cyclase,6.295E-01,8.219E-01,1,Adenylate cyclase,
682,Development_S1P1 signaling pathway,44,6.295E-01,8.084E-01,6.431E-01,8.084E-01,1,Adenylate cyclase,6.295E-01,8.219E-01,1,Adenylate cyclase,
683,Thiamine metabolism,44,6.295E-01,8.084E-01,6.431E-01,8.084E-01,1,SLC44A4,6.295E-01,8.219E-01,1,SLC44A4,
684,Apo-2L(TNFSF10)-induced apoptosis in melanoma,45,6.378E-01,8.084E-01,6.514E-01,8.084E-01,1,XBP1,6.378E-01,8.219E-01,1,XBP1,
685,Development_Negative regulation of WNT/Beta-catenin signaling at the receptor level,45,6.378E-01,8.084E-01,6.514E-01,8.084E-01,1,IBP4,6.378E-01,8.219E-01,1,IBP4,
686,Immune response_TNF-R2 signaling pathways,45,6.378E-01,8.084E-01,6.514E-01,8.084E-01,1,Bcl-2,6.378E-01,8.219E-01,1,Bcl-2,
687,Stem cells_Excitotoxicity of Glutamate in glioblastoma,45,6.378E-01,8.084E-01,6.514E-01,8.084E-01,1,SLC1A2/EAAT2,6.378E-01,8.219E-01,1,SLC1A2/EAAT2,
688,Differentiation of Th2 cells in asthma,45,6.378E-01,8.084E-01,6.514E-01,8.084E-01,1,CCR5,6.378E-01,8.219E-01,1,CCR5,
689,Immune response_IL-4 signaling pathway,94,6.430E-01,8.084E-01,6.430E-01,8.084E-01,2,"Tuberin, Bcl-2",8.807E-01,8.890E-01,1,Bcl-2,
690,Niacin-HDL metabolism,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,HDL proteins,6.459E-01,8.219E-01,1,HDL proteins,
691,"Development_TGF-beta-dependent induction of EMT via RhoA,  PI3K and ILK",46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,TGF-beta 3,6.459E-01,8.219E-01,1,TGF-beta 3,
692,Transcription_Hypoxia- and receptor-mediated HIF-1 activation,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,LRRK2,6.459E-01,8.219E-01,1,LRRK2,
693,Transcription_Androgen Receptor nuclear signaling,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,Androgen receptor,6.459E-01,8.219E-01,1,Androgen receptor,
694,Role of GIP in pathogenesis of type 2 diabetes,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,Bcl-2,6.459E-01,8.219E-01,1,Bcl-2,
695,Anandamide biosynthesis and metabolism,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,PLA2(hGIIA),6.459E-01,8.219E-01,1,PLA2(hGIIA),
696,Regulation of GSK3 beta in bipolar disorder,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,PP2A regulatory,6.459E-01,8.219E-01,1,PP2A regulatory,
697,Dual function of Treg cells in cancer development,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,ROR-gamma,6.459E-01,8.219E-01,1,ROR-gamma,
698,Serotonin - melatonin biosynthesis and metabolism,46,6.459E-01,8.084E-01,6.595E-01,8.084E-01,1,INMT,6.459E-01,8.219E-01,1,INMT,
699,Canonical Leptin pathways in breast cancer,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,ESR1 (nuclear),6.538E-01,8.219E-01,1,ESR1 (nuclear),
700,Development_Schema: FGF signaling in embryonic stem cell self-renewal and differentiation,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,SOX2,6.538E-01,8.219E-01,1,SOX2,
701,Inhibition of remyelination in multiple sclerosis: role of cell-cell and ECM-cell interactions,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,Connexin 32,6.538E-01,8.219E-01,1,Connexin 32,
702,Regulation of mast cell survival in asthma,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,Bcl-2,6.538E-01,8.219E-01,1,Bcl-2,
703,Regulation of lipid metabolism_PPAR regulation of lipid metabolism,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,Fatty acid-binding protein,6.538E-01,8.219E-01,1,Fatty acid-binding protein,
704,TGF-beta signaling via SMADs in breast cancer,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,TGF-beta 3,6.538E-01,8.219E-01,1,TGF-beta 3,
705,Neurophysiological process_Circadian rhythm,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,Dexras1,6.538E-01,8.219E-01,1,Dexras1,
706,Transport_GPR40 signaling pathway in beta cells,47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,CACNA1D,6.538E-01,8.219E-01,1,CACNA1D,
707,wtCFTR and deltaF508 traffic / Membrane expression (normal and CF),47,6.538E-01,8.084E-01,6.674E-01,8.084E-01,1,EBP50,6.538E-01,8.219E-01,1,EBP50,
708,Macrophage and dendritic cell phenotype shift in cancer,100,6.566E-01,8.084E-01,6.763E-01,8.084E-01,2,"ESR1 (nuclear), XBP1",6.566E-01,8.219E-01,2,"ESR1 (nuclear), XBP1",
709,Immune response_NF-AT signaling and leukocyte interactions,48,6.615E-01,8.084E-01,6.751E-01,8.084E-01,1,IGHE,6.615E-01,8.219E-01,1,IGHE,
710,Neuropeptide signaling in pancreatic cancer,48,6.615E-01,8.084E-01,6.751E-01,8.084E-01,1,GRP-R,6.615E-01,8.219E-01,1,GRP-R,
711,Muscle contraction_Relaxin signaling pathway,48,6.615E-01,8.084E-01,6.751E-01,8.084E-01,1,Adenylate cyclase type V,6.615E-01,8.219E-01,1,Adenylate cyclase type V,
712,"Nicotine signaling in dopaminergic neurons, Pt. 1 - cell body",48,6.615E-01,8.084E-01,6.751E-01,8.084E-01,1,nAChR alpha-4,6.615E-01,8.219E-01,1,nAChR alpha-4,
713,Immune response_IL-12 signaling pathway,48,6.615E-01,8.084E-01,6.751E-01,8.084E-01,1,GADD45 gamma,6.615E-01,8.219E-01,1,GADD45 gamma,
714,GLP-1 in beta cell apoptosis in type 2 diabetes,48,6.615E-01,8.084E-01,6.751E-01,8.084E-01,1,Bcl-2,6.615E-01,8.219E-01,1,Bcl-2,
715,Cell adhesion_Integrin-mediated cell adhesion and migration,48,6.615E-01,8.084E-01,6.751E-01,8.084E-01,1,Collagen II,6.615E-01,8.219E-01,1,Collagen II,
716,SLE genetic marker-specific pathways in T cells,101,6.619E-01,8.084E-01,6.816E-01,8.084E-01,2,"ESR1 (nuclear), Bcl-2",6.619E-01,8.219E-01,2,"ESR1 (nuclear), Bcl-2",
717,Glucocorticoids-mediated inhibition of pro-constrictory and pro-inflammatory signaling in airway smooth muscle cells,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,PLA2,6.691E-01,8.219E-01,1,PLA2,
718,Axonal degeneration in multiple sclerosis,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,CACNA1D,6.691E-01,8.219E-01,1,CACNA1D,
719,Cytoskeleton remodeling_Integrin outside-in signaling,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,Collagen II,6.691E-01,8.219E-01,1,Collagen II,
720,Th17 cells in CF (mouse model),49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,ROR-gamma,6.691E-01,8.219E-01,1,ROR-gamma,
721,Tissue Factor signaling in cancer via PAR1 and PAR2,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,Coagulation factor VII,6.691E-01,8.219E-01,1,Coagulation factor VII,
722,Bacterial infections in CF airways,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,SP-D,6.691E-01,8.219E-01,1,SP-D,
723,Development_PEDF signaling,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,Bcl-2,6.691E-01,8.219E-01,1,Bcl-2,
724,Role and regulation of Prostaglandin E2 in gastric cancer,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,Adenylate cyclase,6.691E-01,8.219E-01,1,Adenylate cyclase,
725,Development_G-CSF signaling,49,6.691E-01,8.084E-01,6.826E-01,8.084E-01,1,Bcl-2,6.691E-01,8.219E-01,1,Bcl-2,
726,Main chemotherapy drugs and their action in SCLC cells,100,6.763E-01,8.084E-01,6.763E-01,8.084E-01,2,"p27KIP1, Bcl-2",8.959E-01,9.011E-01,1,Bcl-2,
727,Development_Thromboxane A2 signaling pathway,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,Adenylate cyclase,6.765E-01,8.219E-01,1,Adenylate cyclase,
728,Neurophysiological process_Corticoliberin signaling via CRHR1 ,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,Adenylate cyclase,6.765E-01,8.219E-01,1,Adenylate cyclase,
729,L-Threonine metabolism,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,SLC7A8,6.765E-01,8.219E-01,1,SLC7A8,
730,Development_EDNRB signaling,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,PI3K reg class IB (p101),6.765E-01,8.219E-01,1,PI3K reg class IB (p101),
731,Immune response_Production and main functions of biologically active leukotrienes and Lipoxin A4,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,ABCC11,6.765E-01,8.219E-01,1,ABCC11,
732,Suppression of p53 signaling in multiple myeloma,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,Bcl-2,6.765E-01,8.219E-01,1,Bcl-2,
733,Immune response_Lectin induced complement pathway,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,Clusterin,6.765E-01,8.219E-01,1,Clusterin,
734,PDE4 regulation of cyto/chemokine expression in inflammatory skin diseases,50,6.765E-01,8.084E-01,6.900E-01,8.084E-01,1,Adenylate cyclase,6.765E-01,8.219E-01,1,Adenylate cyclase,
735,Cortisone biosynthesis and metabolism,51,6.838E-01,8.099E-01,6.972E-01,8.099E-01,1,CYP11B2,6.838E-01,8.219E-01,1,CYP11B2,
736,Neurophysiological process_GABAergic neurotransmission,51,6.838E-01,8.099E-01,6.972E-01,8.099E-01,1,GABT,6.838E-01,8.219E-01,1,GABT,
737,Development_Oligodendrocyte differentiation from adult stem cells,51,6.838E-01,8.099E-01,6.972E-01,8.099E-01,1,OATP-A,6.838E-01,8.219E-01,1,OATP-A,
738,Epithelial cell anoikis in COPD,51,6.838E-01,8.099E-01,6.972E-01,8.099E-01,1,Bcl-2,6.838E-01,8.219E-01,1,Bcl-2,
739,HIF-1 in gastric cancer,51,6.838E-01,8.099E-01,6.972E-01,8.099E-01,1,Bcl-2,6.838E-01,8.219E-01,1,Bcl-2,
740,Immune response_NF-AT in immune response,51,6.838E-01,8.099E-01,6.972E-01,8.099E-01,1,BLNK,6.838E-01,8.219E-01,1,BLNK,
741,Development_FGF-family signaling,52,6.908E-01,8.121E-01,7.042E-01,8.121E-01,1,FGFR4,6.908E-01,8.219E-01,1,FGFR4,
742,Glucagon-induced glucose upregulation in type 2 diabetes in liver ,52,6.908E-01,8.121E-01,7.042E-01,8.121E-01,1,Adenylate cyclase,6.908E-01,8.219E-01,1,Adenylate cyclase,
743,Neurophysiological process_Synaptic vesicle fusion and recycling in nerve terminals,52,6.908E-01,8.121E-01,7.042E-01,8.121E-01,1,Complexin,6.908E-01,8.219E-01,1,Complexin,
744,Development_Endothelin-1/EDNRA signaling,52,6.908E-01,8.121E-01,7.042E-01,8.121E-01,1,Adenylate cyclase,6.908E-01,8.219E-01,1,Adenylate cyclase,
745,CoA biosynthesis,52,6.908E-01,8.121E-01,7.042E-01,8.121E-01,1,ENPP1,6.908E-01,8.219E-01,1,ENPP1,
746,Influence of bone marrow cell environment on progression of multiple myeloma,52,6.908E-01,8.121E-01,7.042E-01,8.121E-01,1,PI3K reg class IB (p101),6.908E-01,8.219E-01,1,PI3K reg class IB (p101),
747,Apoptosis and survival_Role of PKR in stress-induced apoptosis,53,6.977E-01,8.132E-01,7.111E-01,8.132E-01,1,PP2A regulatory,6.977E-01,8.219E-01,1,PP2A regulatory,
748,Immune response_Classical complement pathway,53,6.977E-01,8.132E-01,7.111E-01,8.132E-01,1,Clusterin,6.977E-01,8.219E-01,1,Clusterin,
749,Effect of H. pylori infection on apoptosis in gastric epithelial cells,53,6.977E-01,8.132E-01,7.111E-01,8.132E-01,1,Bcl-2,6.977E-01,8.219E-01,1,Bcl-2,
750,ENaC regulation in normal and CF airways ,53,6.977E-01,8.132E-01,7.111E-01,8.132E-01,1,Adenylate cyclase,6.977E-01,8.219E-01,1,Adenylate cyclase,
751,TLRs-mediated IFN-alpha production by plasmacytoid dendritic cells in SLE,53,6.977E-01,8.132E-01,7.111E-01,8.132E-01,1,CAMP,6.977E-01,8.219E-01,1,CAMP,
752,NRF2 regulation of oxidative stress response,54,7.045E-01,8.150E-01,7.178E-01,8.150E-01,1,GSTA3,7.045E-01,8.219E-01,1,GSTA3,
753,Th17 cells in CF,54,7.045E-01,8.150E-01,7.178E-01,8.150E-01,1,ROR-gamma,7.045E-01,8.219E-01,1,ROR-gamma,
754,Neurophysiological process_Dynein-dynactin motor complex in axonal transport in neurons,54,7.045E-01,8.150E-01,7.178E-01,8.150E-01,1,Carboxypeptidase H,7.045E-01,8.219E-01,1,Carboxypeptidase H,
755,Role of IL-23/ T17 pathogenic axis in psoriasis,54,7.045E-01,8.150E-01,7.178E-01,8.150E-01,1,ROR-gamma,7.045E-01,8.219E-01,1,ROR-gamma,
756,Immune response_IFN-gamma actions on extracellular matrix and cell differentiation,54,7.045E-01,8.150E-01,7.178E-01,8.150E-01,1,Collagen II,7.045E-01,8.219E-01,1,Collagen II,
757,Immune response_Platelet activating factor/ PTAFR pathway signaling,55,7.111E-01,8.176E-01,7.243E-01,8.176E-01,1,Adenylate cyclase,7.111E-01,8.219E-01,1,Adenylate cyclase,
758,Tau pathology in Alzheimer disease,55,7.111E-01,8.176E-01,7.243E-01,8.176E-01,1,Tau (MAPT),7.111E-01,8.219E-01,1,Tau (MAPT),
759,"Immune response_T cell co-signaling receptors, schema",55,7.111E-01,8.176E-01,7.243E-01,8.176E-01,1,Collagen II,7.111E-01,8.219E-01,1,Collagen II,
760,Chemotaxis_CCL2-induced chemotaxis,55,7.111E-01,8.176E-01,7.243E-01,8.176E-01,1,PI3K reg class IB (p101),7.111E-01,8.219E-01,1,PI3K reg class IB (p101),
761,PGE2 pathways in cancer,55,7.111E-01,8.176E-01,7.243E-01,8.176E-01,1,Adenylate cyclase,7.111E-01,8.219E-01,1,Adenylate cyclase,
762,Platelet activation as a result of endothelial dysfunction after stenting,56,7.176E-01,8.190E-01,7.307E-01,8.190E-01,1,Adenylate cyclase,7.176E-01,8.222E-01,1,Adenylate cyclase,
763,Development_Keratinocyte differentiation,56,7.176E-01,8.190E-01,7.307E-01,8.190E-01,1,C/EBPalpha,7.176E-01,8.222E-01,1,C/EBPalpha,
764,Role of FSH and Lutropin in ovarian cancer,56,7.176E-01,8.190E-01,7.307E-01,8.190E-01,1,Adenylate cyclase,7.176E-01,8.222E-01,1,Adenylate cyclase,
765,Muscle contraction_Regulation of eNOS activity in cardiomyocytes,56,7.176E-01,8.190E-01,7.307E-01,8.190E-01,1,Adenylate cyclase type V,7.176E-01,8.222E-01,1,Adenylate cyclase type V,
766,Ca(2+)-dependent NF-AT signaling in cardiac hypertrophy,57,7.239E-01,8.203E-01,7.370E-01,8.203E-01,1,Adenylate cyclase type V,7.239E-01,8.222E-01,1,Adenylate cyclase type V,
767,Gamma-Secretase regulation of neuronal cell development and function,57,7.239E-01,8.203E-01,7.370E-01,8.203E-01,1,Tau (MAPT),7.239E-01,8.222E-01,1,Tau (MAPT),
768,Prostaglandin 1 biosynthesis and metabolism,57,7.239E-01,8.203E-01,7.370E-01,8.203E-01,1,ALOX15B,7.239E-01,8.222E-01,1,ALOX15B,
769,CCR7 signaling pathways in dendritic cells in allergic contact dermatitis,57,7.239E-01,8.203E-01,7.370E-01,8.203E-01,1,PI3K reg class IB (p101),7.239E-01,8.222E-01,1,PI3K reg class IB (p101),
770,Immune response_B cell antigen receptor (BCR) pathway,110,7.261E-01,8.186E-01,7.261E-01,8.186E-01,2,"N-Ras, BLNK",9.170E-01,9.203E-01,1,BLNK,
771,Role of integrins in eosinophil degranulation in asthma,58,7.301E-01,8.203E-01,7.431E-01,8.203E-01,1,SP-D,7.301E-01,8.227E-01,1,SP-D,
772,Cell adhesion_Integrin inside-out signaling,58,7.301E-01,8.203E-01,7.431E-01,8.203E-01,1,Collagen II,7.301E-01,8.227E-01,1,Collagen II,
773,Immune response_IL-15 signaling,58,7.301E-01,8.203E-01,7.431E-01,8.203E-01,1,Bcl-2,7.301E-01,8.227E-01,1,Bcl-2,
774,Aberrant production of IL-2 and IL-17 in SLE T cells,58,7.301E-01,8.203E-01,7.431E-01,8.203E-01,1,ROR-gamma,7.301E-01,8.227E-01,1,ROR-gamma,
775,NMDA-independent presynaptic long-term potentiation in Huntington's disease,58,7.301E-01,8.203E-01,7.431E-01,8.203E-01,1,GluR7,7.301E-01,8.227E-01,1,GluR7,
776,Role of B cells in SLE,58,7.301E-01,8.203E-01,7.431E-01,8.203E-01,1,Bcl-2,7.301E-01,8.227E-01,1,Bcl-2,
777,Renal secretion of inorganic electrolytes,59,7.361E-01,8.220E-01,7.491E-01,8.220E-01,1,SLC12A1,7.361E-01,8.231E-01,1,SLC12A1,
778,Signal transduction_Production and main functions of biologically active prostaglandins and Thromboxane A2,59,7.361E-01,8.220E-01,7.491E-01,8.220E-01,1,PGE2R3,7.361E-01,8.231E-01,1,PGE2R3,
779,Regulation of lipid metabolism_G-alpha(q) regulation of lipid metabolism,59,7.361E-01,8.220E-01,7.491E-01,8.220E-01,1,ABCG1,7.361E-01,8.231E-01,1,ABCG1,
780,Development_Regulation of cytoskeleton proteins in oligodendrocyte differentiation and myelination,59,7.361E-01,8.220E-01,7.491E-01,8.220E-01,1,Tau (MAPT),7.361E-01,8.231E-01,1,Tau (MAPT),
781,Cigarette smoke-induced oxidative stress and apoptosis in airway epithelial cells,60,7.420E-01,8.220E-01,7.549E-01,8.220E-01,1,Bcl-2,7.420E-01,8.231E-01,1,Bcl-2,
782,A shift from oxidative to glycolytic muscle fiber phenotype in quadriceps muscles in COPD,60,7.420E-01,8.220E-01,7.549E-01,8.220E-01,1,Fatty acid-binding protein,7.420E-01,8.231E-01,1,Fatty acid-binding protein,
783,Aberrant lipid trafficking and metabolism in age-related macular degeneration pathogenesis,60,7.420E-01,8.220E-01,7.549E-01,8.220E-01,1,Clusterin,7.420E-01,8.231E-01,1,Clusterin,
784,Apoptosis and survival_TNF-alpha-induced ROS-dependent Caspase-3 signaling,60,7.420E-01,8.220E-01,7.549E-01,8.220E-01,1,Bcl-2,7.420E-01,8.231E-01,1,Bcl-2,
785,Oxidative stress_ROS-mediated MAPK activation via canonical pathways,60,7.420E-01,8.220E-01,7.549E-01,8.220E-01,1,SFK,7.420E-01,8.231E-01,1,SFK,
786,Stimulation of gastric acid secretion in gastric cancer,60,7.420E-01,8.220E-01,7.549E-01,8.220E-01,1,Adenylate cyclase,7.420E-01,8.231E-01,1,Adenylate cyclase,
787,Antioxidant effects of statins in COPD,60,7.420E-01,8.220E-01,7.549E-01,8.220E-01,1,RhoB,7.420E-01,8.231E-01,1,RhoB,
788,"Metabolism of L-cysteine, D-cysteine and L-cystine",119,7.472E-01,8.261E-01,7.653E-01,8.261E-01,2,"SLC7A8, SLC1A2/EAAT2",7.472E-01,8.273E-01,2,"SLC7A8, SLC1A2/EAAT2",
789,Induction of mucin secretion in  airway goblet cells by purinergic receptors,61,7.478E-01,8.253E-01,7.606E-01,8.253E-01,1,PP2A regulatory,7.478E-01,8.273E-01,1,PP2A regulatory,
790,Muscle contraction_Oxytocin signaling in uterus and mammary gland,62,7.534E-01,8.261E-01,7.661E-01,8.261E-01,1,PLA2(hGIIA),7.534E-01,8.293E-01,1,PLA2(hGIIA),
791,Renin-Angiotensin-Aldosterone System,62,7.534E-01,8.261E-01,7.661E-01,8.261E-01,1,CYP11B2,7.534E-01,8.293E-01,1,CYP11B2,
792,Immune response_IL-10 signaling pathway,62,7.534E-01,8.261E-01,7.661E-01,8.261E-01,1,Bcl-2,7.534E-01,8.293E-01,1,Bcl-2,
793,Development_Alpha-2 adrenergic receptor activation of ERK,62,7.534E-01,8.261E-01,7.661E-01,8.261E-01,1,Alpha-2A adrenergic receptor,7.534E-01,8.293E-01,1,Alpha-2A adrenergic receptor,
794,Immune response_IL-18 signaling,63,7.590E-01,8.261E-01,7.716E-01,8.261E-01,1,Bcl-2,7.590E-01,8.295E-01,1,Bcl-2,
795,HCV-mediated liver damage and predisposition to HCC via cell stress,63,7.590E-01,8.261E-01,7.716E-01,8.261E-01,1,XBP1,7.590E-01,8.295E-01,1,XBP1,
796,Lacto-series GSL Metabolism,63,7.590E-01,8.261E-01,7.716E-01,8.261E-01,1,G3ST2,7.590E-01,8.295E-01,1,G3ST2,
797,CHDI_Correlations from Replication data_Cytoskeleton and adhesion module,64,7.644E-01,8.261E-01,7.769E-01,8.261E-01,1,PI3K reg class IB (p101),7.644E-01,8.295E-01,1,PI3K reg class IB (p101),
798,TGF-beta-induced fibroblast/ myofibroblast migration and extracellular matrix production in asthmatic airways,64,7.644E-01,8.261E-01,7.769E-01,8.261E-01,1,TGF-beta 3,7.644E-01,8.295E-01,1,TGF-beta 3,
799,Immune response_IFN-alpha/beta signaling via JAK/STAT,64,7.644E-01,8.261E-01,7.769E-01,8.261E-01,1,Bcl-2,7.644E-01,8.295E-01,1,Bcl-2,
800,Myeloid-derived suppressor cells and M2 macrophages in cancer,64,7.644E-01,8.261E-01,7.769E-01,8.261E-01,1,CAT-2,7.644E-01,8.295E-01,1,CAT-2,
801,Polyamine metabolism,64,7.644E-01,8.261E-01,7.769E-01,8.261E-01,1,ABP1,7.644E-01,8.295E-01,1,ABP1,
802,Folic acid metabolism,64,7.644E-01,8.261E-01,7.769E-01,8.261E-01,1,FOLH1 (GCP2),7.644E-01,8.295E-01,1,FOLH1 (GCP2),
803,Plasmalogen biosynthesis,64,7.644E-01,8.261E-01,7.769E-01,8.261E-01,1,PLA2,7.644E-01,8.295E-01,1,PLA2,
804,TNF-alpha and IL-1 beta-mediated regulation of contraction and secretion of inflammatory factors in normal and asthmatic airway smooth muscle,65,7.696E-01,8.261E-01,7.821E-01,8.261E-01,1,PLA2,7.696E-01,8.310E-01,1,PLA2,
805,Unsaturated fatty acid biosynthesis,65,7.696E-01,8.261E-01,7.821E-01,8.261E-01,1,ELOVL2,7.696E-01,8.310E-01,1,ELOVL2,
806,Renal tubulointerstitial injury in Lupus Nephritis ,65,7.696E-01,8.261E-01,7.821E-01,8.261E-01,1,CCR5,7.696E-01,8.310E-01,1,CCR5,
807,Role of Tissue factor-induced Thrombin signaling in cancerogenesis,65,7.696E-01,8.261E-01,7.821E-01,8.261E-01,1,Coagulation factor VII,7.696E-01,8.310E-01,1,Coagulation factor VII,
808,Vitamin B3 and NAD+ metabolism,125,7.713E-01,8.285E-01,7.886E-01,8.285E-01,2,"SLC5A8, ENPP1",7.713E-01,8.313E-01,2,"SLC5A8, ENPP1",
809,Canonical WNT signaling pathway in colorectal cancer,66,7.748E-01,8.278E-01,7.871E-01,8.278E-01,1,Mucin 2,7.748E-01,8.313E-01,1,Mucin 2,
810,Pyruvate metabolism,66,7.748E-01,8.278E-01,7.871E-01,8.278E-01,1,LDHD,7.748E-01,8.313E-01,1,LDHD,
811,Metabolism in pancreatic cancer cells,66,7.748E-01,8.278E-01,7.871E-01,8.278E-01,1,DHE4,7.748E-01,8.313E-01,1,DHE4,
812,Signal transduction_PDGF signaling via JAK-STAT and reactive oxygen species (ROS),66,7.748E-01,8.278E-01,7.871E-01,8.278E-01,1,Bcl-2,7.748E-01,8.313E-01,1,Bcl-2,
813,Eosinophil survival in asthma,67,7.798E-01,8.312E-01,7.921E-01,8.312E-01,1,Bcl-2,7.798E-01,8.336E-01,1,Bcl-2,
814,Production of reactive oxygen species and arachidonic acid metabolites by neutrophils in asthma,68,7.848E-01,8.335E-01,7.969E-01,8.335E-01,1,IL8RA,7.848E-01,8.357E-01,1,IL8RA,
815,Immune response_Sublytic effects of membrane attack complex,68,7.848E-01,8.335E-01,7.969E-01,8.335E-01,1,PI3K reg class IB (p101),7.848E-01,8.357E-01,1,PI3K reg class IB (p101),
816,Lipoprotein metabolism,68,7.848E-01,8.335E-01,7.969E-01,8.335E-01,1,ABCG1,7.848E-01,8.357E-01,1,ABCG1,
817,Immune response_OX40L/ OX40 signaling pathway,69,7.896E-01,8.366E-01,8.016E-01,8.366E-01,1,Bcl-2,7.896E-01,8.377E-01,1,Bcl-2,
818,Immune response_CD16 signaling in NK cells,69,7.896E-01,8.366E-01,8.016E-01,8.366E-01,1,PLA2,7.896E-01,8.377E-01,1,PLA2,
819,Mechanisms of drug resistance in SCLC,70,7.943E-01,8.405E-01,8.062E-01,8.405E-01,1,Bcl-2,7.943E-01,8.417E-01,1,Bcl-2,
820,Development_EGFR signaling pathway,71,7.989E-01,8.424E-01,8.107E-01,8.425E-01,1,MKP-2,7.989E-01,8.424E-01,1,MKP-2,
821,Glutathione metabolism,71,7.989E-01,8.424E-01,8.107E-01,8.425E-01,1,GSTA3,7.989E-01,8.424E-01,1,GSTA3,
822,Transport_Clathrin-coated vesicle cycle,71,7.989E-01,8.424E-01,8.107E-01,8.425E-01,1,Myosin I,7.989E-01,8.424E-01,1,Myosin I,
823,Angiotensin II Signaling in Cardiac Hypertrophy,72,8.034E-01,8.438E-01,8.151E-01,8.443E-01,1,Kv4.3 channel,8.034E-01,8.438E-01,1,Kv4.3 channel,
824,Blood coagulation_Platelet microparticle generation,72,8.034E-01,8.438E-01,8.151E-01,8.443E-01,1,Alpha-2A adrenergic receptor,8.034E-01,8.438E-01,1,Alpha-2A adrenergic receptor,
825,Neolacto-series GSL Metabolism p.1,72,8.034E-01,8.438E-01,8.151E-01,8.443E-01,1,G3ST2,8.034E-01,8.438E-01,1,G3ST2,
826,Aspartate and asparagine metabolism,73,8.078E-01,8.438E-01,8.194E-01,8.469E-01,1,GABT,8.078E-01,8.438E-01,1,GABT,
827,Regulation and signaling of HGF receptor (Met) and MSP receptor (RON) in lung cancer,73,8.078E-01,8.438E-01,8.194E-01,8.469E-01,1,Delta-catenin,8.078E-01,8.438E-01,1,Delta-catenin,
828,Peroxysomal straight-chain fatty acid beta-oxidation,74,8.121E-01,8.438E-01,8.236E-01,8.485E-01,1,ACOX2,8.121E-01,8.438E-01,1,ACOX2,
829,Signal transduction_HTR2A signaling outside the nervous system,74,8.121E-01,8.438E-01,8.236E-01,8.485E-01,1,Adenylate cyclase,8.121E-01,8.438E-01,1,Adenylate cyclase,
830,Ubiquinone metabolism,74,8.121E-01,8.438E-01,8.236E-01,8.485E-01,1,TAT,8.121E-01,8.438E-01,1,TAT,
831,Immune response _CCR3 signaling in eosinophils,77,8.245E-01,8.545E-01,8.356E-01,8.590E-01,1,PI3K reg class IB (p101),8.245E-01,8.545E-01,1,PI3K reg class IB (p101),
832,CHDI_Correlations from Replication data_Causal network (positive correlations),79,8.323E-01,8.605E-01,8.432E-01,8.649E-01,1,PI3K reg class IB (p101),8.323E-01,8.605E-01,1,PI3K reg class IB (p101),
833,L-Arginine metabolism,79,8.323E-01,8.605E-01,8.432E-01,8.649E-01,1,ABP1,8.323E-01,8.605E-01,1,ABP1,
834,B cell signaling in hematological malignancies,80,8.360E-01,8.634E-01,8.468E-01,8.677E-01,1,Bcl-2,8.360E-01,8.634E-01,1,Bcl-2,
835,Vitamin E (alfa-tocopherol) metabolism,81,8.397E-01,8.635E-01,8.504E-01,8.684E-01,1,ACOX2,8.397E-01,8.635E-01,1,ACOX2,
836,Fructose metabolism,81,8.397E-01,8.635E-01,8.504E-01,8.684E-01,1,F16P,8.397E-01,8.635E-01,1,F16P,
837,Immune response_IL-1 signaling pathway,82,8.433E-01,8.635E-01,8.539E-01,8.684E-01,1,Collagen II,8.433E-01,8.635E-01,1,Collagen II,
838,Neurophysiological process_NMDA-dependent postsynaptic long-term potentiation in CA1 hippocampal neurons,82,8.433E-01,8.635E-01,8.539E-01,8.684E-01,1,NR1,8.433E-01,8.635E-01,1,NR1,
839,HETE and HPETE biosynthesis and metabolism,82,8.433E-01,8.635E-01,8.539E-01,8.684E-01,1,ALOX15B,8.433E-01,8.635E-01,1,ALOX15B,
840,Androgen biosynthetic pathways,82,8.433E-01,8.635E-01,8.539E-01,8.684E-01,1,CYP11B2,8.433E-01,8.635E-01,1,CYP11B2,
841,Transport_Intracellular cholesterol transport,83,8.468E-01,8.651E-01,8.573E-01,8.700E-01,1,ABCG1,8.468E-01,8.651E-01,1,ABCG1,
842,Cytoskeleton remodeling_PDGF signaling via calcium and Rho GTPases,83,8.468E-01,8.651E-01,8.573E-01,8.700E-01,1,EBP50,8.468E-01,8.651E-01,1,EBP50,
843,Peroxisomal branched chain fatty acid oxidation,84,8.503E-01,8.675E-01,8.606E-01,8.716E-01,1,ACOX2,8.503E-01,8.675E-01,1,ACOX2,
844,Prostaglandin 2 biosynthesis and metabolism,86,8.569E-01,8.733E-01,8.670E-01,8.771E-01,1,LOXE3,8.569E-01,8.733E-01,1,LOXE3,
845,Cholesterol metabolism,87,8.601E-01,8.755E-01,8.701E-01,8.793E-01,1,ACOX2,8.601E-01,8.755E-01,1,ACOX2,
846,Immune response_The effect of IDO1 on T cell metabolism,89,8.663E-01,8.797E-01,8.761E-01,8.844E-01,1,DHE4,8.663E-01,8.797E-01,1,DHE4,
847,T follicular helper cell dysfunction in SLE,90,8.693E-01,8.817E-01,8.790E-01,8.864E-01,1,KLF2,8.693E-01,8.817E-01,1,KLF2,
848,Glycolysis and gluconeogenesis,94,8.807E-01,8.890E-01,8.899E-01,8.955E-01,1,F16P,8.807E-01,8.890E-01,1,F16P,
849,Bile Acid Biosynthesis,94,8.807E-01,8.890E-01,8.899E-01,8.955E-01,1,ACOX2,8.807E-01,8.890E-01,1,ACOX2,
850,"Signal transduction_Angiotensin II/ AGTR1 signaling via p38, ERK and PI3K",98,8.910E-01,8.973E-01,8.998E-01,9.035E-01,1,CYP11B2,8.910E-01,8.973E-01,1,CYP11B2,
851,Aminoglycoside- and cisplatin-induced hair cell death,112,9.207E-01,9.229E-01,9.280E-01,9.299E-01,1,Bcl-2,9.207E-01,9.229E-01,1,Bcl-2,
852,ATP/ITP metabolism,123,9.383E-01,9.394E-01,9.444E-01,9.454E-01,1,ADAR3,9.383E-01,9.394E-01,1,ADAR3,
853,Mitochondrial beta-oxidation of long-chain saturated fatty acids,125,9.410E-01,9.410E-01,9.470E-01,9.470E-01,1,B-FABP,9.410E-01,9.410E-01,1,B-FABP,
,,,,,,,,,,,,,
